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Arsenic compounds have been used as medicines since ancient times. Recently, arsenic 
trioxide (ATO) was recognized to be an effective treatment modality for acute 
promyelocytic leukemia, being attributed to its differentiation- and apoptosis-inducing 
capabilities. 
Acute megakaryocytic (MK) leukemia (AMKL) is a rare subtype of acute myeloid 
leukemia occurring in children (more prevalent to Down syndrome patients) and adults. 
The relapse rate of AMKL is high and long-term survival is poor in these patients, thus 
highlighting the urgent need for developing alternative treatment protocols. The efficacy 
of ATO on AMKL has not been widely documented. 
i 
Our project aimed at investigating the effects of ATO on proliferation, apoptosis and cell 
cycle progression of two MK cell lines CHRF-288-11 (CHRP; originated from a 
17-month-old child) and MEG-01 (from a 5 5-year-old male). We further studied the 
expressions of apoptotic regulators at mRNA and protein levels in response to ATO. The 
early effects of ATO on gene expressions of these cells were screened by a microarray 
covering 19,200 clones from the human genome. 
Our results demonstrated that ATO at 6 i^M abolished proliferation and induced 
phosphatidylserine extemalization - a hallmark of apoptosis in MK cells. CHRF cells 
seemed to be more vulnerable to ATO in terms of the onset of apoptotic phenotype. We 
also showed that caspase-3 activation and disruption of mitochondrial membrane 
potential by ATO occurred in both cells. Moreover, ATO induced an early cell cycle 
progression delay, precipitating G2/M accumulation. Apoptosis of MK cells occurred 
predominantly in GQ/GI phase as demonstrated by the simultaneous staining with cell 
cycle (7-AAD, BrdU) and apoptotic (caspase-3) markers. 
The changes in the expression of apoptotic signals were monitored by a cDNA microarray. 
We observed trends of up-regulation of caspase-1，Fas and CD 137 mRNA, the latter two 
being confirmed at protein level by flow cytometry. This was the first report 
ii 
demonstrating that CD137 mRNA and protein expressions were increased in response to 
ATO. Whereas down-regulating trend was noted in Mcl-l and DR4 mRNA, a similar 
inclination of cell surface DR4 protein expression was observed. ATO stimulated the 
expression of Bax protein in both MK cells, whereas Bcl-2 levels were decreased in 
CHRP cells. 
In order to identify the early response in MK cells, gene expressions were profiled by a 
19,200 spot-microarray at 4 hours after ATO exposure. Our data demonstrated that mRNA 
expressions of various members of the stress response, including metallothioneins, 
ubiquitin, heat shock proteins and ferritin were increased. The trend of up-regulation was 
also observed in the transcription factor WTl. 
In summary, ATO inhibited MK cells by delaying cell cycle transition, thus retarding 
proliferation, and inducing apoptosis, which might be provoked extrinsically by death 
signals via receptors and intrinsically by perturbing the mitochondrial integrity. Our 
findings indicated that ATO might be a promising new drug in treating AMKL. We 
provided the first evidence that CHRF cells were responsive to ATO, and its difference 
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C H A P T E R 1 
G E N E R A L INTRODUCTION 
SECTION 1.1 Historical Background and Application of Arsenic 
Trioxide as an Anti-cancer Agent 
Arsenic (symbol: As, atomic number: 33) is a semi-metal that has three allotropic forms. 
, Arsenicals have been known and used since ancient times. Yellow arsenic (AS2S3) was 
used as a pigment by Assyrians (Greek: arsenikon). Free elemental arsenic rarely exists, 
though its compounds are widely distributed in nature, being present in minute quantities 
in the soil, the sea and in living matter. Arsenic occurs mainly in the trivalent and 
pentavalent states as compounds of arsenite and arsenate. White arsenic or arsenic 
trioxide (ATO) is one example of the trivalent arsenicals. It is a white or transparent solid 
in the form of glassy, shapeless lumps or a crystalline powder, and has no odor or taste. 
Conventionally, ATO is known by its empirical formula AS2O3, but vapor density 
determinations show that it exists as AS4O6 molecules (Gorby, 1994) (Figure 1.1). 
1 , 
The ease for arsenicals to undergo reduction-oxidation (redox) reactions, to a very large 
extent, determines the toxic nature of arsenic compounds. Mitochondria, where many 
redox reactions take place, are thus sensitive to arsenicals, especially the trivalent arsenite 
(Del Razo et al.，2001). 
For a long time, arsenic compounds were considered the perfect poison and were thought 
to have claimed the lives of many, including Napoleon Bonaparte (Antman, 2001). On the 
other hand, arsenicals have been used as a therapeutic agent for more than two thousand 
years in the treatment of ulcers, tuberculosis, syphilis, and many other ailments (Klaassen, 
. 2 0 0 1 ) . Discovered in 1786，the Fowler's solution (1 % w/v ATO in KHCO3) had been a 
remedy prescribed for a range of infectious and malignant diseases, including chronic 
myelogenous leukemia (CML) (Kwong and Todd, 1997; Antman, 2001). When concerns 
were raised about the toxicity and carcinogenicity of arsenicals (Huff et al., 2000)，the 
medicinal use of arsenic in the Western world was superseded by modem chemotherapy 
(Kwong and Todd, 1997). 
In 1971, a Chinese group in Harbin conducted a series of clinical trials of ATO on various 
types of cancer, and they found that ATO seemed to be effective in treating CML, 
lymphoma, esophageal cancer, and in particular, acute promyelocytic leukemia (APL) 
2 , 
(Zhang et al, 2001). Then another group from Shanghai reported that among 15 relapsed 
APL patients, a complete remission was achieved in nine of 10 patients treated with ATO 
alone and five of five patients treated with ATO in combination with chemotherapeutic 
drugs (Chen et al., 1996; Shen et al.，1997). This marked the revitalization of ATO in the 
modem medical field. In 2000，the approval of the use of ATO (under the name Trisenox) 
in the treatment of APL by the US Food and Drug Administration (Cohen et al” 2001) has 
accelerated the research on ATO. Numerous in vitro and in vivo studies have been 
undertaken in non-APL hematological and sold tumor cell lines. Clinical trials in several 
malignancies have been embarked, and to date a promising application in multiple 
- myeloma has been demonstrated. A brief summary of the use of ATO as an anti-cancer 
agent is listed in Table 1.1. 
SECTION 1.2 Arsenic Trioxide Induces Apoptosis in Cancer Cells 
Apoptosis，or programmed cell death, is exemplified by a loss of adhesion and rounding, 
cell shrinkage, chromatin condensation, nuclear fragmentation and plasma membrane 
blebbing (Kerr et al, 1972; Wyllie et al., 1980). Such morphological changes are 
associated with a distinct set of biochemical markers, including intemucleosomal 
deoxyribonucleic acid (DNA) cleavage (Wyllie, 1980)，which leads to the appearance of a 
3 , 
"DNA ladder" in agarose gel electrophoresis (Cohen et aL, 1994), loss of plasma 
membrane asymmetry due to phosphatidylserine extemalization (Martin et al,, 1995), and 
proteolytic cleavage of various intracellular substrates (Fischer et al., 2003). The whole 
apoptotic process is tightly regulated, and although the signaling pathways are diverse, 
they eventually converge on a common death execution machinery. 
1.2.1 The Intrinsic and Extrinsic Pathways of Apoptosis Initiation 
Apoptosis can be initiated by a number of stimuli. According to a classical view, such 
- stimuli are either of intrinsic or extrinsic origin. Extrinsic death signals are intercepted by 
cell surface-bound transmembrane death receptors and intrinsic insults are translated to 
orders of d eath by them itochondria. Although the two p athways d iffer i n m echanism, 
both mainly rely on a class of evolutionarily conserved cysteine proteases known as 
caspases (cysteine aspartyl-specific proteases), to amplify and to transmit death signals 
(Cryns and Yuan, 1998). The human caspase family, currently consists of 11 members, is 
classified functionally into two main streams, inflammatory (caspase-1，-5, -11) and 
pro-apoptotic caspases, the latter is further grouped into initiator (caspase-2, -8，-9，-10， 
-12) and e ffector c aspases (caspase-3,-6, -7) (Degterev etaL,2003). A11 caspases are 
synthesized as zymogens, and have to be cleaved and processed to become active. The 
4 , 
downstream effectors, activated by the upstream initiators (Thomberry et al, 1997)，are 
capable of degrading a panel of functional proteins including transcription factors，signal 
transducers, and cell cycle regulators, to name but a few (Fischer et al., 2003). 
In the extrinsic pathway (Figure 1.2), the first step in the transduction of extracellular 
death signal is the stimulation of various members of the tumor necrosis factor (TNF) 
receptor superfamily, TNF receptor 1 (TNF-Rl), Fas and TNF-related apoptosis-inducing 
ligand (TRAIL) receptors (TRAIL-R1/DR4, TRAIL-R2/DR5), with their respective 
ligands (TNF-a, FasL, TRAIL) (Peter and Krammer, 2003; Wang and El Deiry, 2003). 
. . A d a p t o r molecule Fas-associated death domain (FADD) or TNF receptor associated death 
domain (TRADD) is recruited to the activated receptor via the death domain (DD) or the 
death effector domain (DED) (Thorbum, 2004)，which further interacts with two 
pro-caspase-8 (or pro-caspase-10) molecules, forming the death-inducing signaling 
complex (DISC) (Chen and Wang, 2002). Upon recruitment, pro-caspase-8 or -10 
molecules dimerize and become activated to initiate apoptosis by direct cleavage of 
downstream effector caspases (Walczak and Krammer, 2000). 
The mitochondrion is the key component of the intrinsic pathway (Figure 1.2). In 
response to stressors, such as ultraviolet or y-irradiation, genotoxic or cytotoxic drugs and 
5 , 
reactive oxygen species (ROS), the integrity of mitochondrial membrane is compromised 
(Kroemer and Reed, 2 000). As a consequence，cytochrome c, normally residing in the 
intermembrane space of the mitochondrion, is released into the cytosol (Saelens et al.’ 
2004). Free cytochrome c molecules, in the presence of dATP, mediate Apaf-1 (apoptotic 
^rotease-flctivating /actor-7) oligomerization, forming a caspase-activating complex 
apoptosome (Li et al.’ 1997). The oligomerized complex then engages pro-caspase-9 
molecules through interactions between the caspase recruitment domains (CARD), and 
facilitates activation of the zymogen (Cain et al, 2002), which in turn initiates a whole 
cascade of downstream caspase activation (Slee et al” 1999). 
Cytochrome c is just one of the many pro-apoptotic factors released from the 
mitochondria (Figure 1.2). Concurrently, Smac (second mitochondrial activator of 
caspases) (Du et al, 2000), HtrA2 (^igh temperature requirement protein A2) (Suzuki et 
al” 2001), AIF (apoptosis-mducing/actor) (Lorenzo et al., 1999) and endonuclease G 
(Davies et al, 2003) are found to be liberated as well. Different from cytochrome c, 
which directly initiates the caspase cascade (in the form of apoptosome), Smac and HtrA2 
keep caspase activity unchecked by sequestering cytosolic inhibitors of apoptosis (lAP), a 
group of proteins that suppresses the maturation of caspases (Salvesen and Duckett, 2002). 
AIF and endonuclease G, however, are not associated with caspases. When released into 
6 , 
the cytosol, AIF translocates to the nucleus, where it induces chromatin condensation and 
DNA fragmentation (Cande et aL, 2002). Endonuclease G synergizes with AIF and 
promotes DNA degradation (Li et al., 2001). 
Given the pro-apoptotic nature of the proteins sequestered in the mitochondria, 
permeabilization of the outer mitochondrial membrane must be under strict control. The 
mapping of Bcl-2 {B-ceW CLL//ymphoma 2) to the outer mitochondrial membrane, and 
the ability of Bax (5CL2-associated X protein) to form ion channels in synthetic 
membranes, raises the possibility that Bcl-2 family members might be regulators of the 
_ mitochondrial apoptotic pathway (Brenner et al, 2000) (Figure 1.2). Bcl-2 family 
members are classified by the Bcl-2 homology (BH) domains they possess. Whereas 
anti-apoptotic members Bcl-2, BC1-XL, and Mcl-l have all four BH domains (BHl -
BH4)，those that promote cell death including Bax, Bak and Bok lack BH4. Distant 
relatives are the BH3-only proteins, such as Bid, Bad and Bnip3, which are all 
pro-apoptotic (Burlacu, 2003). Several models have been postulated to explain the 
interplay between different members of the Bcl-2 clan. In one model, Bid-induced 
activation of Bax/Bak is normally blocked by Bcl-2, which upon death stimuli is 
displaced by Bad to initiate the apoptotic pathway (Letai et al., 2002). Other hypotheses 
exist, demonstrating the complexity of the issue (Cory et al., 2003). 
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1.2.2 The Convergence of Pathways 
So far, extrinsic and intrinsic pathways are seen as two independent strategies that only 
converge at the level of caspase activation. Nevertheless, Bcl-2 has been shown to prevent 
Fas-mediated apoptosis in certain cell types (Scaffidi et al” 1998). This was later 
explained by the fact that active caspase-8 not only cleaves downstream caspase, but also 
Bid (Luo et al., 1998) to yield a truncated form (tBid), which participates in the 
mitochondrial pathway (Madesh et al., 2002; Brustovetsky et al., 2003) (Figure 1.2). 
Caspase-2 is a unique member of the caspase family. Despite that it shares sequence 
homology with initiator caspases, its cleavage specificity is closer to effector caspases 
(Troy and Shelanski, 2003). Caspase-2 has been proposed to be the apical caspase in a 
DNA damage response. As the only caspase found in the nucleus, pro-caspase-2 is 
activated in response to DNA damage, and induces mitochondrial permeabilization 
(Norbury and Zhivotovsky, 2004). Recently, caspase-2 was suggested to be activated in 
parallel with caspase-8 in the TRAIL DISC, facilitating direct or indirect Bid cleavage 
(Wagner et al, 2004) (Figure 1.2). 
A third initiation pathway involves in the endoplasmic reticulum (ER), where 
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pro-caspase-12 is localized and activated by the ER stress (Nakagawa et al., 2000). 
Perturbations of the ER homeostasis would lead to the activation of the ER stress 
response (or unfolded protein response) (Rutkowski and Kaufman, 2004)，and eventually, 
apoptosis. The mitochondria have been suggested to be one of the mediators in 
ER-induced cell death. Signaling between the two organelles, possibly by Ca^ "", alters the 
balance between anti- and pro-apoptotic members of the Bcl-2 family, thus initiating the 
mitochondrial pathway (Breckenridge et al” 2003) (Figure 1.2). 
1.2.3 Induction of Apoptosis by Arsenic Trioxide 
1.2.3.1 Controversies in the Involvement of the Extrinsic Pathway 
In the hepatocellular carcinoma cell line HLE，Kito et al. (2002) concluded that the 
activation of caspase-8 and Bid truncation in the presence of ATO, precipitated 
cytochrome c release from mitochondria and subsequent caspase-9 maturation. 
Nevertheless, how caspase-8 was activated per se was not addressed. In two other studies， 
caspase-8 activation was found to be independent of Fas or TNF-Rl, since the blocking of 
the death receptors could not rescue ATO-induced apoptosis (Ishitsuka et al.’ 2000; 
Kitamura et al, 2000). Interestingly, ATO increased active caspase-8, TNF-Rl and 
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TRADD expression levels, but not Fas and FADD, in CD4+ T helper cells, and that 
specific TNF-Rl blocking antibodies could significantly improved viability (Yu et al., 
2002). Similar findings were reported in melanoma (Ivanov and Hei, 2004). The 
involvement of Fas in ATO-mediated apoptosis is also controversial. While Liao et al. 
(2004) proposed that the Fas pathway was initiated in keratinocytes, Rojewski et al. 
(2004b) demonstrated it was unnecessary in lymphoid cells. TRAIL receptors are 
components of the extrinsic pathway. It has been shown that DR4 and DR5 expressions 
were up-regulated by ATO in myeloma cells, where cleavage of either pro-caspase-8 or -9 
was noted, depending on the specific cell line (Akay and Gazitt, 2003; Liu et al,, 2003). 
1.2.3.2 Arsenic Trioxide, Oxidative Stress and the Mitochondria 
ATO affects the physiological redox balance in a cell by producing ROS and consuming 
the cellular reducing agents (Harris and Shi, 2003). ROS formation has been known to be 
induced by ATO in a number of cell lines (Qian et al., 2003; Shi et al.’ 2004)，and its 
contribution to ATO-mediated apoptosis was recognized, when Chen et al (1998) 
demonstrated that the addition of ROS scavengers could suppress ATO-induced DNA 
fragmentation in fibroblasts. The apoptotic activity of ATO has been associated with the 
cellular oxidative status that it was enhanced by inhibiting glutathione regeneration (using 
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buthionine sulfoximine) and suppressed by antioxidants (e.g. DTT) (Cai et al, 2000; 
Gartenhaus et al., 2002; Yi et al” 2002). 
Increased cellular production ofROS by ATO results in oxidative stress, which may lead 
to DNA damage, lipid peroxidation and inactivation/denaturation of proteins/enzymes 
whose functions/conformation depend on the thiol groups. The polarized mitochondrial 
membrane potential (A\j/m) is maintained by controlling the opening of the permeability 
transition pore complex. It has been shown that certain thiol groups are essential in the 
regulation of this pore complex, and the redox balance is carefully adjusted by glutathione. 
„ ATO, as an oxidizing agent，could increase the probability of pore opening by 
crosslinking the thiol groups (Petronilli et al., 1994; Costantini et al., 1996). Later, Cai 
and colleagues (2000) demonstrated ATO could induce A\|/m collapse, which could be 
enhanced by buthionine sulfoximine, or suppressed by DTT. Depolarization of Avj/ni was 
then suggested to be a common feature in ATO-mediated leukemic cell death, after the 
examination of several cell lines of myeloid and lymphoid lineages (Rojewski et al, 
2004a). 
Members of the Bcl-2 family are important regulators of the mitochondrial pathway of 
apoptosis. Bcl-2 down-regulation in response to ATO is commonly observed in a variety 
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of cell systems, including the APL cell line NB4 (Chen et al., 1996)，other leukemia and 
lymphoma cells {Zhx et al” 2003b) and neuroblastoma (Ora et al., 2000). Furthermore, 
by silencing BCL2 gene expression, the sensitivity of cells towards ATO was found to be 
increased (Zhang and Lei, 2003). In another study, overexpression ofBcl-2 essentially 
protected HeLa cells from apoptosis (Woo et al.’ 2002). The modulation of Bax 
expression by ATO are relatively less well studied, but up-regulation (Seol et al” 2001) 
and activation (Karlsson et al.’ 2004) have been reported. 
1.2.3.3 Caspase-3 Activation in Arsenic Trioxide-mediated Apoptosis 
The earliest pieces of evidence of caspase involvement were reported at almost the same 
time by two separate groups. Soignet et al. (1998) analyzed bone marrow mononuclear 
cells from APL patients on ATO therapy and found increased expression of caspase-3. On 
the other hand, Chen et al (1998) challenged fibroblasts with ATO (80 |iM) and observed 
an increase of caspase-3 activity, with a concomitant decrease in pro-caspase-3 protein 
level. Later, in another report, caspase-3 cleavage product was seen in 1 ^M ATO-treated 
lymphoma cells (Zhu et al., 1999b). Caspase-3 appeared to be commonly activated by 
ATO in a number of cell lines, including B-cell leukemia (Akao et al.’ 1998)，MC/CAR 
myeloma (Park et al., 2000)，neuroblastoma cells (Akao et al., 1999)，APL cell line NB4 
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(Kitamura et al., 2000) and T-cell leukemia (Ishitsuka et al., 2000). 
SECTION 1.3 Arsenic Trioxide Perturbs the Cell Division Cycle 
The cell division cycle, or cell cycle in short can be identified morphologically as two 
distinct stages: mitosis (M)，the process of nuclear division; and interphase, the interlude 
between two M phases. Under a light microscope, the M phase encompasses prophase 
(chromatin condensation), metaphase (alignment at the mitotic spindle), anaphase, 
(separation of sister chromatids), telophase (disintegration of spindle and reformation of 
.nuclear membrane) and cytokinesis (cell fission). Interphase takes up the remaining, 
much larger fraction of time in the cycle, and is divided into three phases, Gi，S and G2, 
according to biochemical parameters. The Gi and G2 phases are so called because they are 
seen as intervals or ‘‘gaps，，between M phase and another landmark event: DNA synthesis 
(hence the name S phase). In the Gi or G2 phases, the cell prepares and makes the 
decision to commit itself to DNA replication or mitosis respectively. The time required 
for one cycle varies, depending on the cell type and organism. In some circumstances, 
cells in Gi do not proceed to S and enter a quiescent state, called Go, and can re-enter the 
cell cycle some time later (Cooper and Hausman, 2004) (Figure 1.3). 
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1.3.1 The Cell Cycle Oscillator 
The driving force of the cell cycle is the cyclic assembly, activation, and disassembly of 
regulatory complexes, which consist of two protein families: cyclins and 
cyclin-dependent kinases (Cdk). 
Cyclins are so called because they undergo a cycle of synthesis and degradation in each 
division cycle of the cell (Darzynkiewicz et al., 1996). Cyclins are the regulatory subunits 
of Cdks. The docking of cyclins to Cdks not only activates the holoenzymes, but also 
provides substrate specificities. Because of the periodicity of cyclin expression, Cdks can 
•be activated only at specific times during the cell cycle，to phosphorylate downstream 
protein targets involved in the transition of cell cycle phases (Morgan, 1995) (Figure 1.3). 
In early Gi, the cell integrates extracellular signals that determine its commitment to the 
cell cycle (Sherr, 1994). Induced by the continual presence of growth factors, Cdk4 and 
Cdk6 would assemble with D-type cyclins (Dl, D2 and D3) to facilitate progression 
through Gi by phosphorylating the retinoblastoma protein (pRb) (Kato et al.’ 1993). pRb 
normally exists in a hypophosphorylated state and sequesters the E2F transcription factor 
family. Upon phosphorylation by cyclin D/Cdk4/6 complexes, E2F is released and free to 
activate (or repress) a plethora of peripheral genes essential for Gi/S progression (Dyson, 
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1998) (Figure 1.4). Cyclin E associates with Cdk2 (Koff et al., 1992)，with its activity 
peaking at the Gi/S boundary, probably cooperates with the D-type cyclin complexes to 
inactivate pRb (Sears and Nevins, 2002). Apart from partnering with cyclin E, Cdk2 also 
binds cyclin A near the start of S phase, a process thought to be essential in the initiation 
of DNA replication (Resnitzky et al., 1995). Progression from S to G2/M requires the 
collaboration of two complexes, cyclinA/Cdkl and cyclin B/Cdkl. Cyclin B, synthesized 
during late S and G2 phases, binds to Cdkl, yet the inactive state of the complex is 
maintained by phosphorylation of Cdkl. At the end of G2 phase, Cdkl is 
dephosphorylated by Cdc25 phosphatase, thus activating the complex (Strausfeld et al； 
-1991). 
1.3.2 DNA Damage and Cell Cycle Checkpoints 
In the cell cycle, the forward machinery is under constant invigilation so as to coordinate 
the entire cell division program. One such monitoring pathway, known as the checkpoint, 
senses various types of structural defects in DNA and induces a multifaceted cellular 
response that activates DNA repair and delays cell cycle progression, usually in the Gi 
and/or G2/M phases (Elledge, 1996; Lengauer et al, 1998). 
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In response to DNA damage, the checkpoint sensors ATM (ataxia telangiectasia mutated) 
and ATR {ATM and 丞ad3 related) are activated and in turn stimulate a series of signals 
leading to the inhibition ofGi/S and G2/M progression (Banin et al.’ 1998; Tibbetts et al” 
1999). 
The Gi checkpoint pathway is initiated when Cdc25A is degraded upon receiving signals 
from the transducers Chkl and/or Chk2, both downstream of ATM and ATR. The 
end-point target of this cascade is the inhibition of S phase entry, which is achieved by 
preventing the recruitment of DNA polymerases onto replication complexes (Falck et al., 
2001). The maintenance of Gi arrest is essentially mediated through p53 (Bartek and 
丄ukas，2001) and its downstream product p21, which inhibits the cyclinD/Cdk4 and 
cyclin E/Cdk2 complexes, preventing E2F-dependent transcription of S phase genes (el 
Deiry et al., 1994; Harper et al” 1995) (Figure 1.4). 
The G2/M checkpoint is operated either via p53 or Chk2 kinase, both subsequently 
leading to the inhibition of the cyclin B/Cdkl complex (Melo and Toczyski, 2002). 
Intermediate signals of the p53 pathway include the 14-3-3a protein, which exports cyclin 
B out of the nucleus, and p21，which sequesters the cylin B/Cdkl complex (Taylor and 
Stark, 2001). Chk 2 directly acts on Cdc25C, preventing the activation of cylin B/Cdkl 
(Herzinger et al., 1995) (Figure 1.4). 
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In a broad sense, cell cycle arrest is a survival strategy by which cells prevent the 
propagation of potentially damaging genetic insults. If the damage is mild, interruption of 
the cell cycle allows the damage to be repaired, or if the harm is deleterious and incurable, 
the entire cell is eradicated by apoptosis (Norbury and Zhivotovsky, 2004). 
Apart from participating in cell cycle checkpoints, p53 is also one of the major signal 
integrators that determines cell death (Vogelstein et al, 2000). In response to stresses, p53 
may transactivate a large number of apoptotic genes, such as APAFl, BAX, TNFRSF6 
(Fas) and TNFRSFIOB (DR5) (Vousden and Lu, 2002) as well as cell cycle control genes. 
Recent studies have provided evidence that a novel class of proteins, ASPP (ankyrin 
repeat, domain and 忍roline-rich domain containing proteins), is an apoptotic-specific 
activator of p53, which directs the cell towards death instead of arresting cells at 
checkpoints (Slee and Lu, 2003). 
1.3.3 Induction of Cell Cycle Arrest by Arsenic Trioxide and its Association with 
Apoptosis 
Known to be a DNA damaging agent, it is not surprising that ATO might interfere with 
the cell cycle. ATO induces G2/M delay in human fibroblasts, and the mechanism could 
be associated with the accumulation of inactive cyclin B/Cdkl (Yih et al., 1997)，as well 
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as the increase in p53 level, and its downstream products (Yih and Lee, 2000). Inhibition 
of cyclin B/Cdkl is likely to be an important mechanism of G2/M arrest, possibly either 
through the up-regulation of p21, as in head and neck tumor cell line PCI-1 (Seol et al., 
1999), or correlated with the curbing of Cdc25 family of phosphatases (Park et al” 2000; 
Chen et al” 2002). 
However, the necessity of p53 seems to depend on the cell type. Using a panel of 
leukemia and lymphoma cell lines, Zhu and colleagues (1999b) concluded that ATO 
delayed cell cycle progression, without changes in p53 protein level. Nevertheless, Zhao 
et al. (2002) demonstrated that G2/M arrest was accompanied by up-regulation of p53 in 
two glioblastoma cell lines. Interestingly, additional arrest in Gi was found in cells 
harboring wildtype, whereas the mutated 0nes 0nly arrested cells in G2/M (Zhu etai, 
1999b; Liu et al,, 2003). Recent studies also suggested that Gadd45 (growth arrest and 
DNA Jamage-inducible protein 45a) was induced in response to ATO, possibly be 
controlled in a p53-indepenednt manner (Chen et al., 2001), repressed cyclin B/Cdkl 
(Zhu et al, 1999a; Li et al, 2003b). 
The link between ATO-mediated cell cycle arrest and apoptosis was first suggested by Ma 
et al (1998). They demonstrated that at low dose ATO (2 ^iM), G2/M arrested NB4 cells 
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selectively underwent apoptosis, whereas at a high concentration (8 |iM), the preference 
was lost. Similar results were obtained in hepatocellular carcinoma cells, where apoptotic 
cells were more commonly found in the G2/M compartment (Zhang et al.’ 2003). Another 
group reported that, by using intermediate concentrations of ATO (5 — 10 |iM), they 
observed delayed transition in both Gi and G2 phases, with G2 cells more susceptible to 
ATO insult, since the retardation of progression and the extent of apoptosis in G2 were 
greater (McCabe，Jr. et al., 2000). 
Comparing the effects of ATO on cell cycle progression, Huang et al. (2002) found that 
prolongation of Gi and G2 phases occurred in low doses of ATO (5 |iM or less)-treated 
HL-60 cells (derived from APL), and high doses (greater than 25 ^M) abrogated the cell 
cycle specificity of apoptosis. On the other hand, CD34+ cells (hematopoietic progenitors) 
were resistant to even high ATO concentrations, and were mostly arrested at GQ/GI. Their 
results not only suggested preferential killing of malignant cells by ATO, but that the cell 
cycle position might be associated with resistance to ATO insult. 
Mitotic arrest due to ATO has been documented in panels of myeloid leukemic at 
anaphase (Li and Broome, 1999) and solid tumor cell lines at metaphase (Ling et al, 
2002)，but the former group proposed that polymerization of tubulin was inhibited by 
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ATO, whereas the latter argued for an increased microtubule polymerization. On the other 
hand, Halicka and colleagues (2002) provided evidence in HL-60 and U937 myeloid cells 
that the block was at prophase and prometaphase, which was associated with increases in 
phosphorylated histone H3 and cyclin B1 expression. They also showed that the arrest 
would eventually lead to apoptosis. 
SECTION 1.4 Acute Megakaryocytic Leukemia and Arsenic 
Trioxide 
Acute m egakaryocytic 1 eukemia (AMKL) i s a rare s ubtype of a cute m yeloid 1 eukemia 
(AML). Though collectively known as M7 in the French-American-British (FAB) 
classification system (Bennett et al.’ 1985), AMKL represents a heterogeneous group of 
disorders, each having unique blast cell morphology, immunophenotype and cytogenetics 
(Duchayne et al., 2003). Infants, adults and Down syndrome patients are the most 
AMKL-susceptible populations (Gassmann and Loffler，1995). The heterogeneity is best 
illustrated by their prognosis, of which children are, in general, better than adults, and that 
the outcome is the best in the Down syndrome group (Garderet et al； 2004). 
Currently, chemotherapy is the choice of treatment but clinical evidence has suggested 
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that the long-term outcome is usually poor (Tallman et al, 2000; Pagano et al, 2002). 
Bone marrow transplantation offers a better alternative to post remission therapy 
(Garderet et al.，2004)，but transplantation is not always practical as it is largely 
determined by the availability of HLA-matched donors. Alternative treatment strategies 
should be considered to improve the outcome of AMKL. 
In view of the breakthrough in APL therapy using ATO, Lu et al. (1999) first raised the 
possibility of extending ATO in treating AMKL. In four megakaryocytic (MK) cell lines, 
they showed that ATO retarded cell proliferation and induced apoptosis by various assays, 
including morphological examination, DNA fragmentation analysis and terminal 
deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling 
(TUNEL) assay. By observing cell morphology, members of the same group later 
proposed t hat ATO c ould a Iso i nduce m itotic a rrest i n M K c e l l s ( Alemany and Levin, 
2000). Jing et al (2002) in their study of the effects of ATO on cell lines derived from 
blast crisis of CML, agreed that MEG-01 underwent apoptosis in the presence of ATO. 
Findings from these studies form the basis of the current investigation, which moved 
further to elucidate the m echanism and signals involved in ATO-mediated apoptosis in 
MK cells. 
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Given the heterogeneous nature of AMKL, we decided to choose two MK cell lines as 
models of the young-children and adult group. Human MK cell line CHRF-288-11 
(CHRF) was derived from an orbital metastasis in a 17-month-old infant with AMKL and 
myelofibrosis. This adherent CHRF line has a doubling time of approximately 33 hours 
(Witte et al, 1986; Fugman et al” 1990). Another human MK cell line MEG-01 was 
derived from the bone marrow of a 55-year-old male with CML in megakaryoblastic 
crisis. The growth property of MEG-01 is mixed in nature, which consists of both 
adhesion and suspension. The doubling time ranges from 36 to 48 hours (Ogura et al., 
1985). 
By comparing the morphology and the cell surface expressions of cluster determinant 
(CD) 42b and CD61, van der Vuurst et al. (1997) concluded that MEG-01 represented an 
early stage of development, and that CHRF was in the category of late stage of maturation. 
Thus through working on CHRF and MEG-01 cells, we wished to get a clearer picture on 
the actions of ATO in AMKL. 
22 , 
Table 1.1 Some Recent Studies on the Treatment of Malignancies with ATO. 
Type of Malignancy In vitro I In vivo Study Clinical Trial 
Bladder transitional cell (Pu et al.，2002) (Small et al., 2003) 
carcinoma 
Cervical carcinoma (Chun et al.’ 2002) 
Colon carcinoma (Maeda et al., 2004) 
Esophageal carcinoma (Shen et al., 2003) 
Gastric carcinoma (Liang et al., 2003) 
Glioblastoma (Kanzawa et al., 2003) 
Head and neck cancer (Seol et al” 1999) 
Hepatocellular carcinoma (Kito et al., 2002) 
Lung carcinoma (Maeda et al” 2004) 
Lymphoid leukemia/lymphoma (Zhang et al” 1998; Lu et (Ravandi and van 
al” 2003; Nasr et al., 2003) Besien，2003) 
Mammary carcinoma (Maeda et al, 2004) (Lai et al.，2003) 
Melanoma (Ivanov and Hei, 2004) 
Myeloid leukemia/myeloma (Chen et al” 1997; (Shen et al” 1997; 
Rousselot et al., 1999; Hussein et al., 
• Nimmanapalli et al., 2003; 2004) 
Korper et al., 2004) 
Nasopharyngeal carcinoma (Li et al.’ 2002) 
Neuroblastoma (Ora et al, 2000) 
Osteosarcoma (Xiao et aL, 2002) 
Ovarian carcinoma (Ling et al., 2002) 
Pancreatic carcinoma (Li et al., 2003b) 
Prostate carcinoma (Maeda et al., 2001) 
Renal cell carcinoma (Hyun et al., 2003) (Vuky et al” 2002) 
23 , 
力 A S 
O / \ O 
A S � � Z A S 
O ^ O 
Figure 1.1 Chemical Structure of Arsenic Trioxide 
Though arsenic trioxide is commonly known by its empirical formula 
AS2O3, vapor density determinations show that each molecule exactly 
consists of four arsenic atoms and six oxygen atoms in units of AsOs 
joined by oxygen bridges. 
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Figure 1.2 Schematic Diagram of the Extrinsic and Intrinsic Apoptotic 
Pathways. 
Apoptosis can be activated either by extrinsic death stimuli, or by 
various intrinsic insults. The essence of the extrinsic pathway is the 
stimulation of death receptors to form the DISC, which initiates 
apoptosis by direct cleavage of downstream effector caspases. Intrinsic 
death stimulus induces the release of cytochrome c from the 
mitochondria, triggering the formation of the apoptosome and the 
processing of caspase-9. The death receptor and mitochondrial 
pathways are interconnected through Bid, which unleashes cytochrome 
c-releasing activity of Bax upon cleavage by caspase-2/8/10. In 
addition, Ca^ "^  released from the ER is proposed to enter the 
mitochondrion, where it provokes cytochrome c release. Refer to the 
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\ ^ I B B ^ / l ^ C y c l m E X Y ® ^ ^ ^ 3 Figure 1.3 Schematic Diagram of the Cell Division Cycle. 
Classically, the cell cycle was broadly divided into mitosis and 
interphase. It was later discovered that the interphase was actually 
made up of three phases: Gi, S and G2. The unidirectional cycling is 
mainly controlled by several cyclin/Cdk complexes, which are active 
only at specific periods of time. Refer to the text (Section 1.3) for 
further details. 
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Figure 1.4 Schematic Diagram of Cell Cycle Checkpoint Controls. 
DNA damage activates ATM and ATR, which transducer their signals 
via p53 and Chkl and Chk2. In the Gi/S checkpoint, Cyclin D/Cdk4 
(or Cdk6) and cyclin E/Cdk2 complexes are the targets of inactivation, 
which aim at preventing cells from entering S phase. Whereas cyclin 
B/Cdkl complex is inhibited by various means in the G2/M checkpoint, 






























































































































































































































C H A P T E R 2 
OBJECTIVES 
AMKL is a heterogeneous disease of which the treatment outcomes by traditional 
chemotherapy have been unsatisfactory. The overall objective of our project was to study 
the effects of the novel agent ATO on the proliferation and apoptosis of two MK cell lines 
CHRF and MEG-01 in culture. We further investigate the mechanisms of apoptosis 
mediated by signals of the intrinsic and extrinsic pathways as well as the acute response 
of gene expressions to ATO. 
The specific aims of the present study were to investigate: 
(1) Effects of ATO on cell proliferation, apoptosis, mitochondrial integrity and cell 
division cycle profiles of MK cell lines (Chapter 4) 
The dose- and time-dependence effects of ATO on CHRF and MEG-01 were assessed by 
the trypan blue exclusion assay. Apoptosis was confirmed and quantitated by Annexin V 
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binding of externalized phosphatidylserine, and active caspase-3 expression, using flow 
cytometry. Mitochondrial integrity, which is usually compromised in cell demise, was 
monitored by JC-1 staining. The cell cycle kinetics in response to ATO was addressed by 
staining with propidium iodide, 5-bromo-2'-deoxyuridine (BrdU) and caspase-3. 
(2) Effects of ATO on the expression of apoptotic signals in MK cell lines (Chapter 5) 
By an apoptotic pathway-specific complementary DNA (cDNA) microarray, messenger 
ribonucleic acid (mRNA) expressions of the regulators in response to ATO were recorded. 
Some of the candidate genes were confirmed at the protein level, by flow cytometry or 
immunoblotting. 
(3) Effects of ATO on gene expression profiles of MK cell lines by microarray analysis 
(Chapter 6) 
The early or direct response of CHRF and MEG-01 to ATO was studied by their global 
gene expression profiles, using a cDNA microarray comprising 19,200 clones from the 
human genome. 
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C H A P T E R 3 
M E T H O D O L O G Y 
SECTION 3.1 Materials 
All culture reagents were either pre-sterilized by the manufacturer or filter-sterilized (0.22 
|im) upon reconstitution. Other reagents were routinely autoclaved. Reagents were 
purchased from Sigma Chemical Co. (St. Louis, MO, USA) and stored at 4 °C unless 
otherwise specified. 
Agarose was obtained from GIBCO (Invitrogen, Grand Island, NY, USA). Agarose gel, 1 
% (w/v) was prepared by heating 0.5 g of agarose in 50 mL of 1 x TBE buffer until 
complete dissolution. When the agarose solution was cooled slightly, 2.5 i^L of ethidium 
bromide was added to give a final concentration of 0.5 |ig/mL. 
Ammonium persulfate (APS), 10 % (w/v) was prepared by dissolving 1 g of APS in 10 
mL of double distilled water (ddHzO). It was stored at -20 °C and protected from light. 
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Annexin V: FITC Apoptosis Detection Kit was obtained from BD Pharaiingen (San 
Diego, C A, USA). Included in this kit were 10 x Annexin V b inding bufFer, Annexin 
V-fluorescein isothiocyanate (FITC) and 50 )ig/mL propidium iodide (PI) staining 
solution. Working 1 x Annexin V binding buffer was freshly made by diluting the 10 x 
stock solution in ddH20. 
Antibodies used in are summarized in Table 3.1. 
ApoAlert Mitochondrial Membrane Sensor Kit was a gift from BD Clontech (Palo 
Alto, CA, USA). Included in this kit were BD MitoSensor Reagent (JC-1; 5 mg/mL) and 
Incubation Buffer. The former component was stored at -80 °C. Immediately prior to use, 
JC-1 was diluted 1,000 times in Incubation Buffer, vortexed, and centrifUged at 20,800 x 
g for 5 minutes to remove aggregates. 
Arsenic trioxide (ATO) was obtained from Pharmalab (Lane Cove, NSW, Australia) as 1 
mg/mL (5.055 mM) injection solution, which had been adjusted to pH 7 - 9 and 
contained no preservative. 
Bovine serum albumin (BSA) protein standard, 2 mg/mL was prepared by dissolving 
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0.02 g ofBSA in 10 mL ofddH20. It was stored at -20 °C. 
BrdU Flow Kit was a gift from BD Pharmingen. Included in this kit were 
FITC-conjugated anti-BrdU antibody, BD Cytofix/Cytoperm buffer, 10 x BD Perm/Wash 
buffer, BD Cytoperm Plus buffer, 7-amino-actinomycin D (7-AAD), BrdU (10 mg/mL) 
and deoxyribonuclease (DNase; 1 mg/mL). The kit was stored at 4 °C, while the latter two 
components at -20 Working 1 x BD Perm/Wash buffer was made by diluting the 
stock solution in ddHzO. Just before use, BrdU was diluted inlMDM to 1 mM (32 x 
dilution), and DNase was diluted in PBS to 0.3 mg/mL. 
CyScribe First-Strand cDNA Labelling Kit was obtained from Amersham Biosciences 
(Little Chalfont，Buckinghamshire, UK). Included in this kit were anchored oligo(dT), 5'x 
CyScript buffer, 0.1 M DTT, dUTP nucleotide mix for labeling with CyDye-dUTP, 1 mM 
Cyanine 3 (Cy3)-dUTP, 1 mM Cyanine 5 (Cy5)-dUTP and 100 U/^iL of CyScript reverse 
transcriptase. The kit was stored at -20 
DC Protein Assay Reagents Package was obtained from Bio-Rad Laboratories 
(Hercules, CA，USA). Included in this package were Reagent A (an alkaline copper 
tartrate solution) and Reagent B (a dilute Folin Reagent), both protected from light. 
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Denaturing sample loading buffer, 2 x was prepared as a 10 mL solution, composed of 
2 mL of 10 X TBE, 3 g of Ficoll-Paque (Amersham Biosciences), 1 mg of bromophenol 
blue and 2 g of urea. 
ECL Western Blotting Detection Reagents (ECL detection reagents 1 and 2) were 
obtained from Amersham Biosciences. They were protected from light. 
Electrophoresis sample buffer, 2 x was composed of 0.75 M tris(hydroxy-
methyl)aminomethane (Tris base), 4 % (w/v) sodium dodecyl sulfate (SDS), 20 % (v/v) 
glycerol, 1.25 % (v/v) 2-mercaptoethanol and 0.5 % (w/v) bromophenol blue. 
Ethidium bromide (10 mg/mL) was prepared by dissolving 10 mg of ethidium bromide 
in 1 mL of ddHzO. It was protected from light. 
FACS Permeabilizing Solution was obtained from BD Immunocytometry Systems 
(BDIS; San Jose, CA, USA) as 10 x stock solution. It was protected from light. Working 
1 X solution was freshly made by diluting the 10 x stock in ddHsO. 
GEArray Q Series Human Apoptosis Gene Array Kit, printed with 96 cDNA 
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fragments involved in apoptosis as quadruplet (tetra-spot format) on a nylon membrane, 
was obtained from Super Array Bioscience Corp. (Frederick, MD, USA). The genes were 
grouped into eleven categories according to their functional and structural features (Table 
3.2). Included in this kit were GEArray Q Series Human Apoptosis Gene Array 
membranes, Buffer AF (GEAprimer mix), GEAhyb Hybridization Solution，GEAblocking 
Solution Q，Alkaline Phosphatase-Streptavidin, 5 x Buffer F (Washing Buffer), Buffer G 
(AP Assay Buffer) and CD?-Star Substrate. 
GEArray AmphoLabeling-LPR Kit w as obtained from SuperArray B ioscience Corp. 
Included in this kit were Buffer P (RT Primer), RNase-free water, lOxRT Buffer, Buffer L 
(LPR Buffer), LE (DNA Polymerase) and 10 x Stop Solution C. Before use for the first 
time, Buffer BN was made by combining 50 pL of 10 x RT Buffer, 1 i^L of 1 M DTT, and 
50 \iL ofdNTP mix, which contained 5 mM dATP, 5 mM dCTP and 5 mM dGTP and 0.5 
mM dTTP (Roche Diagnostics GmbH, Penzberg, Germany). The kit was stored at -20 °C. 
Gel mix (resolving gel), 10 % was composed of 2.5 mL of 40 % acryl-
amide/bis-acrylamide solution, 50 |iL of 10 % APS, 5 i^L of N，N，N，，N，-tetramethyl-
ethylenediamine (TEMED; Bio-Rad Laboratories), 2.5 mL of 1.5 M Tris, pH 8.8, 100 i^L 
of 10 % SDS and 4.85 mL ofddHzO. APS and TEMED were added only before use. 
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Human 19K Array, pre-spotted with 19,008 characterized and unknown human 
expressed sequence tags (EST) (total 19,200 spots) on a glass slide, was obtained from 
the Ontario Cancer Institute Microarray Centre (University Health Network, University of 
Toronto, Toronto, ON, Canada). 
Human MK cell line CHRF-288-11 (CHRF) was a gift from Dr. B.H. Chong 
(University of New South Wales, Sydney, Australia). MEG-01 was a gift from Dr. H. 
Saito (Nagoya University School of Medicine, Nagoya, Japan). 
Iscove's modified Dulbecco's medium (IMDM) was obtained from GIBCO. The 
powder (17.7 g) was reconstituted in 1 L ddHzO buffered with 3.024 g/L sodium 
bicarbonate (GIBCO), sterilized by filtration through a 0.22 i^m vacuum driven bottle top 
filter (Millipore, Bedford, MA, USA) under aseptic conditions. Before use, the plain 
medium was supplemented with penicillin-streptomycin (10 U/mL penicillin G sodium 
and 10 [ig/mL streptomycin sulfate; GIBCO), and 10 % (v/v) heat-inactivated (56 °C for 
30 minutes) fetal bovine serum (FBS; GIBCO), forming the complete MDM medium. 
Lysis buffer was composed of 20 mM 4-(2-hydroxyethyl)piperazine-1 -ethanesulfonic 
acid (HEPES), 2 mM ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid 
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(EGTA), 50 mM P-glycerophosphate, 1 % (w/v) Triton X-100,10 % (v/v) glycerol, 1 mM 
DTT and 1 x protease inhibitor (Protease I nhibitor Cocktail Tablet; Roche Diagnostics 
GmbH). 
Paraformaldehyde (PFA) in PBS, 1 % (w/v) was prepared by heating 0.1 g of PFA 
powder (Merck KGaA, Darmstadt, Germany) in 0.5 mL of ddHzO and one drop of 1 M 
sodium hydroxide to 80 °C with constant shaking until the powder dissolved, followed by 
the addition of 9.5 mL of PBS. 
Phosphate-buffered saline (PBS), pH 7.4 was obtained from GIBCO. 
Propidium iodide (PI), 2 mg/mL stock solution was prepared by dissolving PI powder 
in PBS. It was stored at -20 °C and protected from light. 
Ribonuclease A (RNase A) was obtained from Boehringer Mannheim (Mannheim, 
Germany). It was prepared by dissolving in ddHsO at a concentration of 10 mg/mL. It 
was stored at -20 °C. 
RNeasy Mini Kit was obtained from Qiagen (Hilden, Germany). Included in this kit were 
Buffer RLT, Buffer RWl, Buffer RPE and RNase-free water. Before use for the first time, 
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Buffer RLT w as supplemented with 2-mercaptoethanol at a final concentration of 10 
pL/mL，and 4 parts of 100 % ethanol was added to 1 part of Buffer RPE. 
Sodium dodecyl sulfate (SDS), 10 % (w/v) was prepared by dissolving 100 g of SDS in 
1 LddH20. 
Sodium saline citrate buffer (SSC), 20 x was prepared by dissolving 175 g of sodium 
chloride and 88 g of trisodium citrate dihydrate (BDH Laboratory Supplies, Poole, UK) in 
1 L ddHzO，adjusted to pH 7.0. 
I 
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Stacker mix (stacking gel), 4 % was composed of 0.5 mL of 40 % acryl-
amide/bis-acrylamide solution, 25 i^L of 10 % APS, 5 i^L of TEMED, 1.25 mL of 1.5 M 
Tris base, pH 8.8, 50 ^L of 10 % SDS and 3.17 mL of ddH20. APS and TEMED were 
added only before use. 
TBS - Tween-20 was freshly made by adding 0.5 % (v/v) Tween-20 to TBS. 
Transfer buffer was composed of 50 mM Tris base and 38 mM glycine. 
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Tris-borate-EDTA buffer (TBE), 10 x was prepared by dissolving 108 g ofTris base, 55 
g of boric acid (Riedel-de Haen, Seelze，Germany) and 40 mL of 0.5 M ethylene-
diamine-N,N,N',N'-tetraacetric acid (EDTA), pH 8 in 1 LddHzO. 
Tris-glycine running buffer was composed of 50 mM Tris base, 38 mM glycine and 1 % 
(w/v) SDS, adjusted to pH 8.3. 
Tris-buffered saline (TBS) was composed of 10 mM Tris base and 0.15 M sodium 
chloride. 
Trypan blue stain, 0.4 % (w/v) was obtained from GEBCO. It was used without prior 
dilution. 
ViaProbe (7-aminoactinomycin D solution) was obtained from BD Pharmingen. 
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SECTION 3.2 Methods 
3.2.1 Culture of Megakaryocytic Cells and Their Treatment with Arsenic 
Trioxide 
3.2.1.1 Maintenance of Cell Lines 
CHRF and MEG-01 cells were maintained in complete IMDM medium in a fully 
humidified atmosphere of 5 % CO2/95 % room air at 37 °C. They were cultured in 25 cm^ 
flasks (BD Falcon, Franklin Lakes, NJ, USA) and were subcultured when the cells 
reached confluence, typically every 3 to 4 days. Both adhered and suspended cells were 
recovered using a cell scraper (NUNC; Nalge Nunc Intl., Naperville, IL, USA). The cell 
suspension was centrifuged at 200 x g for 5 minutes and resuspended in fresh complete 
M D M medium at a cell density of 5 x /mL. 
3.2.1.2 Treatment with Arsenic Trioxide 
Twenty-four hours prior to the addition of ATO, CHRF or MEG-01 cells were seeded in 
6-well polystyrene plates (BD Falcon), or in 25 cm^ flasks in medium with 5 % (v/v) FBS 
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at a density of 5 x lO* cells/mL. ATO was diluted in IMDM as 10 x indicated 
concentrations, and subsequently added to the treatment groups to reach the final working 
concentrations. Control groups were prepared by adding medium only. The cells were 
then incubated at 37 °C for the duration indicated. 
At the end of the incubation period, cells were recovered by a cell scraper. The cell 
suspension was centrifuged at 200 x g for 5 minutes, and subsequently washed twice with 
PBS supplemented with 2 % (v/v) FBS. This cell suspension was the starting material for 
all assays. The cells were enumerated with a hemacytometer (Reichert-Jung, Cambridge 
Instruments Inc., Buffalo，NY, USA). 
3.2.2 Effects of Arsenic Trioxide on Cell Proliferation, Apoptosis, Mitochondrial 
Integrity and Cell Division Cycle Profiles of Human Megakaryocytic 
Leukemia Cell Lines 
3.2.2.1 Trypan Blue Exclusion Assay 
CHRP or MEG-01 cells were treated with 0，1，2，4，6 or 8 i^M ATO for 24，48 or 72 
hours. Ten microliters of the cell suspension was mixed with 10 |iL of trypan blue stain 
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and loaded into the counting chamber of a hemacytometer. The cells were viewed under a 
light microscope at 100 x magnification. T he number of viable (clear) and non-viable 
(blue) cells overlying four 1-mm^ quadrants of the counting chamber was determined. 
The counts were translated into concentration (cells/mL) and viability (%) by the 
following equations: 
Cell concentration (/mL) = total cell count x 0.5 x /mL 
Viability (%) = viable cell count / total cell count x 100 % 
3.2.2.2 Quantitation of Externalized Phosphatidylserine 
Externalized phosphatidylserine was quantified by the Annexin V: FITC Apoptosis 
Detection Kit according to the manufacturer's instructions. CHRF or MEG-01 cells were 
treated with 0，1，2, 4，6 or 8 |iM ATO for 24 or 48 hours. One hundred thousand cells 
were resuspended in 100 pL of 1 x Annexin V binding buffer, and incubated with 5 |iL of 
Aimexin V-FITC and 5 \iL of PI for 15 minutes at ambient temperature in the dark. 
Following the addition of 400 \iL of 1 x binding buffer, the stained cells were analyzed by 
FACScan flow cytometer (BDIS), equipped with a 488 nm argon excitation laser. 
Annexin V-FITC fluorescence was detected using a 530/30 nm bandpass filter (FLl 
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channel). PI was detected using a 585/42 nm bandpass filter (FL2 channel). Ten thousand 
events were acquired and stored by the Lysis II software, while analyses were done using 
the CellQuest software (both from BDIS). 
3.2.2.3 Quantitation of Active Caspase-3 Expression 
CHRF or MEG-01 cells were treated with 0，1，2，4, 6 or 8 [iM ATO for 24 or 48 hours. 
One million cells were treated with 500 \iL of 1 x FACS Permeabilizing Solution for 15 
minutes at ambient temperature in the dark. Permeabilized cells were washed with PBS 
and stained with 20 i^ L of PE-conjugated polyclonal antibody against the active form of 
caspase-3 for 30 minutes at ambient temperature in the dark. Cells were washed again 
with PBS, and then fixed in 400 ^L of 1 % PFA in PBS. The fluorescence signal was 
detected at the FL2 channel by flow cytometry. Ten thousand events were acquired. 
3.2.2.4 Assessment of Mitochondrial Integrity 
Mitochondrial integrity was assessed by monitoring the mitochondrial membrane 
potential changes using the ApoAlert Mitochondrial Membrane Sensor Kit according to 
the manufacturer's instructions. CHRF or MEG-01 cells were treated with 0 or 6 |iM ATO 
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for 24 or 48 hours. One million cells were treated with 1 mL of diluted JC-1 and were 
incubated for 15 minutes at 37 °C in a 5 % CO2 incubator. The cells were then washed 
with 1 mL of Incubation Buffer, and resuspended again in 1 mL of Incubation Buffer. The 
monomers and aggregates of JC-1 were detected at the FLl and FL2 channels 
respectively. Twenty thousand events were acquired. 
3.2.2.5 Analysis of Cell Division Cycle Profile 
CHRF or MEG-01 cells were treated with 0，4，6 or 8 \iM ATO for 1, 4，8，16，24 or 48 
hours. Cells (1 x 10 )^ were fixed with cold 70 % (v/v) ethanol at 4 overnight. Fixed 
cells were washed with PBS twice and treated with 0.5 mL of 50 )ig/mL PI in PBS and 50 
\iL of RNase A for 30 minutes at ambient temperature in the dark. Cell cycle analysis was 
performed by flow cytometry. Cells labeled with PI were detected at the FL2 channel with 
a doublet discrimination module. Thirty thousand events were acquired. Subsequent 
analyses were performed using the ModFit LT software (version 3.1 SPl, Verity Software 
House, Topsham, ME, USA). 
3.2.2.6 Analysis of Cell Cycle Kinetics by BrdU labeling 
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Cell cycle kinetics was analyzed using the BrdU Flow Kit according to the manufacturer's 
instructions. CHRP cells were equilibrated in MDM supplemented with 5 % FBS for 24 
hours, then pulse-labeled with BrdU (final concentration 10 pM) for 45 minutes. The cells 
were washed twice with MDM (with 5 % FBS), and further incubated in the presence or 
absence of 6 ^M ATO for 0，4，8 or 24 hours and were finally harvested. One million cells 
were fixed and permeabilized in 100 |iL of BD Cytofix/Cytoperm buffer for 15 minutes at 
ambient temperature, and washed with 1 mL of BD Perm/Wash buffer. The cells were 
resuspended in 100 jiL of BD CytoPerm Plus buffer and incubated for 10 minutes on ice, 
followed by washing with 1 mL of BD Perm/Wash buffer. The cells were re-fixed in 100 
|.iL of BD Cytofix/Cytoperm buffer for 5 minutes at ambient temperature, then subjected 
to another washing with 1 mL of BD Perm/Wash buffer. DNase (100 i^L) was added to 
the cell pellet for 1 hour at 37 °C to allow the exposure of incorporated BrdU. After 
washing with 1 mL of BD Wash/Perm buffer the cells were stained with FITC-conjugated 
anti-BrdU for 20 minutes at ambient temperature. The cells were washed with 1 mL of 
BD Perm/Wash buffer, and resuspended in 20 |iL of 7-AAD. One milliliter of PBS 
(supplemented with 3 % FBS and 0.09 % sodium azide) was added before analyzed by 
flow cytometry. FITC fluorescence was monitored at the FLl channel, and 7-AAD 
fluorescence was detected at the FL3 channel (650 nm longpass filter) with a doublet 
discrimination module. Thirty thousand events were acquired. 
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3.2.2.7 Identification of Cell Cycle Specificity of Caspase-3 Expression 
For the simultaneous detection of active caspase-3 expression and DNA content, CHRF 
cells were treated with or without 6 i^M ATO for 24 hours, and were processed as 
described in Section 3.2.2.3, After the final washing, the cells were incubated in the 
presence of 20 |iL of ViaProbe (7-AAD) and 50 ^L of RNase A for 30 minutes at ambient 
temperature in the dark. The fluorescence signals of PE-anti-active caspase-3 and 7-AAD 
were detected at channels FL2 and FL3 respectively by flow cytometry. In one 
experiment, the BrdU labeling protocol (Section 3.2.2.5) was modified such that 20 i^L of 
PE-conjugated polyclonal antibody against the active form of caspase-3 was added along 
side with FITC-conjugated anti-BrdU. The cells were then analyzed by flow cytometry. 
Thirty thousand events were acquired. 
3.2.3 Effects of Arsenic Trioxide on the Expression of Apoptotic Signals in 
Human Megakaryocytic Leukemia Cell Lines 
3.2.3.1 Effects of Arsenic Trioxide on mRNA Expression Levels of Apoptotic 
Regulators 
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Extraction and Quantitation of Total Cellular Ribonucleic Acid (RNA) 
CHRF or MEG-01 cells were treated with 0 or 6 |iM ATO for 4, 8 or 16 hours. The 
supernatant was aspirated completely after centrifligation of the cell suspension at 10,600 x 
g for 10 minutes. Then the pellet, containing 5 x 10^  cells, was resuspended in 350 i^L of 
Buffer RLT and h omogenized by p assing t hrough d i l l Vi -gauge n eedle ten t imes. The 
resulting lysate was mixed thoroughly with 350 |a.L of 70 % ethanol, and then applied to an 
RNeasy mini column, sitting in a 2 mL collection tube. The column was subject to 
centrifligation at 10,600 x g for 1 minute and the flow-through was discarded. The column 
was washed once with 700 ^L of Buffer RWl, followed by 500 |xL of Buffer RPE. For each 
washing, the column was centrifuged at 10,600 x g for 1 minute and the flow-through was 
discarded. Another 500 |iL of Buffer RPE was added to the column and was spun at 20,800 
X g for 2 minutes to dry the membrane completely. Total cellular RNA was eluted with 30 
i^L of RNase-free water, by spinning for 1 minute at 10,600 x g. 
The q uantity and p urity o f RNA in e ach p reparation w ere d etermined by t heir o ptical 
densities (OD) at 260 nm and 280 nm. One microliter of RNA preparation was mixed with 
99 i^L of 0.5 M Tris buffer, loaded to a quartz cuvette, and measured by a 
spectrophotometer (GeneQuant RNA/DNA Calculator; Pharmacia, Uppsala, Sweden). The 
concentration of RNA (in |ig/|aL) was calculated by (OD260 x 40) / (1/500 x 1000). The 
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purity was reflected by the ratio O D 2 6 0 / 2 8 0 . Normally, a ratio of 1 . 8 to 2.0 was considered 
satisfactory and was mandatory in order to proceed to later steps. 
One microgram of RNA, mixed with 2 x denaturing sample loading buffer to a final 
concentration of 1 x, was loaded to 1 % agarose gel stained with ethidium bromide for 
electrophoresis. RNA was considered intact when the 28S (5.0 kb) and 18S (1.9 kb) 
ribosomal RNA (rRNA) bands were sharp and clear, and that the 28S rRNA band was 
approximately twice as intense as the 18S rRNA band. 
Reverse Transcription and Labeling of cDNA 
Total RNA was used as a template for biotinylated probe synthesis using the GEArray 
AmphoLabeling-LPR Kit. Freshly prepared total cellular RNA (3 }ig) (Section 3.2.3.1) 
was annealed with 1 ^L of Buffer P at 70 °C for 3 minutes and kept at 37 °C for 10 minutes. 
Then, the RNA was reverse transcribed in the presence of 4 )iL of Buffer BN，1 \xL of 
RNasin ribonuclease inhibitor (Promega, Madison, WI, USA) and 1 i^L ofM-MLV reverse 
transcriptase (Promega) at 37 °C for 25 minutes. The reaction was stopped by heating at 
85 for 5 minutes. The cDNA was mixed with 18 i^L of Buffer L, 9 i^L of Buffer AF, 2 
|iL of biotin-16-2 ‘ -deoxyuridine-5 'triphosphate (biotin-16-dUTP; Roche Diagnostics 
GmbH) and l^iL of LE. The resulting mixture was subjected to 85 °C for 5 minutes, 
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followed by 30 cycles of linear polymerase reaction (85 1 minute; 50 1 minute; 72 
1 minute), and 5 minutes at 72 °C in a Hybaid TouchDown thermal cycler (TD8500; 
Thermo Hybaid, Ashford, Middlesex, UK). The reaction was stopped by adding 5 \iL of 
Buffer C. 
Hybridization and Wash Conditions 
The labeled cDNA probes were denatured by heating at 94 °C for 2 minutes. The 
denatured probes, together with pre-warmed 750 i^L GEAprehyb solution, containing 
GEAhyb Hybridization Solution and 0.1 mg/mL salmon sperm DNA (Invitrogen) at 60 
was applied to the GEArray (pre-hybridized in 2 mL of GEAprehyb solution at 60 °C for 
2 hours) and left in a hybridization chamber (Hybaid Midi 14; Thermo Hybaid) at 60 °C 
overnight with continuous agitation. The GEArray was washed twice with 2 x SSC - 1 % 
SDS，and twice with 0.1 x SSC 一 0.5 % SDS. All washings were done at 60 °C for 15 
minutes. The membrane was incubated with 2 mL o f GEAblocking S olution Q for 40 
minutes at ambient temperature. GEArray was then incubated with 2 mL of 
AP-conjugated streptavidin (1:7500 dilution in 1 x Buffer F) for 10 minutes. The array 
was washed four times with 4 mL of 1 x Buffer F, 5 minutes each, and rinsed twice with 3 
mL of Buffer G. For detection, 1 mL of CDP-Star chemiluminescent substrate was added 
to the membrane and incubated at room temperature for 5 minutes. The GEArray was 
48 
blotted dry and wrapped with a sheet of plastic wrap. 
Image Acquisition 
The chemiluminescence signal generated was detected using X-ray film (Hyperfilm MP; 
Amersham Biosciences). The array was exposed for various durations to ensure linearity 
and to avoid saturation of the signals. The film was digitized by a desktop scanner (HP 
ScanJet 7400C with ScanJet XPA; Hewlett-Packard, Palo Alto, CA, USA), at a resolution 
of 200 dpi, to obtain an 8-bit grayscale TIFF image. 
Data Analysis and Normalization 
The location of spots and quantification of signal intensities were performed using the 
Quant Array software (version 3.1; Packard Bioscience, Billerica, MA, USA) and the 
histogram quantitation method. Raw intensities were corrected by s ubtracting the local 
background from each spot, and the average intensity of internal pUC18 DNA negative 
control and the blank. The background-subtracted intensities were then checked against 
the selection criteria (intensity value and spot diameter > 0). Only those passing the 
criteria were normalized by dividing them by the average intensity of the house-keeping 
genes (peptidylprolyl isomerase A). Gene expression ratios (treatment versus control) are 
reported as the average from two independent experiments. , 
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3.2.3.2 Effects of Arsenic Trioxide on Protein Expression Levels of Apoptotic 
Regulators “ 
3.2.3.2.1 Flow Cytometric Analysis 
Fas and CD 137 
CHRP or MEG-01 cells were treated with 0 or 6 |iM ATO for 4，8，16，24 or 48 hours. 
One million cells were resuspended in 100 )iL of PBS and incubated with 20 jiL of 
FITC-conjugated mouse anti-human Fas or PE-conjugated mouse anti-human CD 137 for 
15 minutes at ambient temperature in the dark. The cell suspension was washed once with 
PBS and fixed in 400 i^L of 1 % PFA in PBS. The fluorescence signals of Fas and CD 137 
were detected at FLl and FL2 channels respectively by flow cytometry. FITC- or 
PE-conjugated IgGiq isotype was included in each experiment to detect non-specific 
binding. Ten thousand events were acquired. 
Death Receptors (DR) 4 and DR5 
CHRF or MEG-01 cells were treated with 0 or 6 i^M ATO for 48 hours. One million cells 
were resuspended in 100 |LIL of PBS and incubated with 2 |IL of primary antibody (mouse 
anti-human DR4 or DR5) for 30 minutes at 4 °C. The cell suspension was washed twice 
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with PBS and stained with 1 ^L of secondary antibody (FITC-conjugated rat anti-mouse 
IgG) in 50 fiL of PBS-for 30 minutes at 4 °C in the dark. The stained cells were washed 
twice with PBS and fixed in 400 ^L of 1 % PFA in PBS. The fluorescence signal of DR4 
or DR5 was detected at the FLl channel by flow cytometry. IgGici was included as the 
isotypic control. Ten thousand events were acquired. 
3.2.3.2.2 Western Blot Analysis 
Preparation and Quantitation of Total Protein Extract 
CHRF or MEG-01 cells were treated with 0 or 6 i^M ATO for 0，8，16 or 24 hours for the 
detection of Bax and Bcl-2 expressions. Total cell lysate was prepared by adding 300 |iL 
of lysis buffer to PBS-washed cell pellet (2 x lO?)，incubated at 4 °C for 30 minutes and 
mixed gently at 5-minute intervals, followed by sonication, using the Soniprep 150 (MSE 
Scientific Instruments, Sussex, UK) at power 5 for 20 seconds. The lysate was then 
centrifUged at 17,900 x g for 10 minutes at 4 °C. The supernatant, which contained 
protein, was recovered and stored at -70 °C. 
Protein concentrations were measured using the DC Protein Assay. Protein sample and 
standards (prepared by mixing BSA with ddHsO) at 5 p.L were added in duplicate to 
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96-well microplate. Reagent A (25 i^L) and reagent B (200 jiL) were added to each 
sample and standard. The microplate was gently agitated and the absorbance (650 - 750 
nm) was measured by a microplate reader (MR5000; Dynatech Laboratories, Chantilly, 
VA，USA). The concentration of the protein sample was determined from a standard 
curve, made by plotting the absorbance against BSA standard concentrations. 
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE electrophoresis apparatus (Mini PROTEAN II Electrophoresis Cell; Bio-Rad 
Laboratories) was assembled according to the instructions provided. Gel mixes (4 % 
stacking gel and 10 % resolving gel) were prepared and cast in the apparatus. The protein 
samples (40 - 60 昭 of whole cell lysate) were mixed with an equal volume of 2 x 
electrophoresis sample buffer and boiled for 5 minutes at 95 °C. Molecular weight 
standards (Cruz Marker; Santa Cruz Biotechnology Inc.) at 1 |LIL (1.6 i^g) and 10 ^L of 
samples were loaded onto the gel. The gel was then electrophoresed at 120 V in the 
presence of Tris-glycine running buffer. 
Electroblotting 
Polyvinylidene fluoride (PVDF) membrane (Hybond-P, Amersham Biosciences) was first 
pre-wetted with absolute methanol and rinsed with cold (4 °C) transfer buffer, then placed 
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on top of the polyacrylamide gel (rinsed with cold transfer buffer), and sandwiched 
between Trans-Blot fiber pads and 3 mm chromatography paper (Whatman grade), both 
soaked in transfer buffer. The Mini Trans-Blot cell (Bio-Rad Laboratories) was assembled 
and filled with cold transfer buffer. Electroblotting was performed at 150 mA for 2 hours. 
Probing of Proteins with Antibodies 
The PVDF membrane was soaked in 5 % non-fat milk (Carnation; Nestle-Shuangcheng 
Co., Shuangcheng, Heilongjiang, PRC) overnight at 4 °C, and washed with TBS. The 
membrane was incubated with primary antibody in TBS - Tween 20 at 4 °C overnight 
with gentle rotation. Then the membrane was washed with TBS — Tween 20 at ambient 
temperature for 10 minutes six times, 8 minutes twice; and rinsed once with TBS for 5 
minutes. The membrane was then incubated with the secondary antibody for 2 hours at 
ambient temperature with gentle rotation. After incubation, the membrane was washed 
with TBS - Tween 20 at ambient temperature for 10 minutes six times, and rinsed once 
with TBS for 5 minutes. 
Image Acquisition 
The membrane was incubated with the ECL Reagent (freshly prepared by mixing equal 
volumes of Reagent 1 and Reagent 2) for 1 minute at ambient temperature. The 
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membrane was exposed to Hyperfilm MP and developed by autoradiography. 
Data Analysis and Normalization 
The band intensity was determined by the Molecular Analyst software (version 1.3; 
Bio-Rad Laboratories) after scanning of the film by a densitometer (Bio-Rad 
Laboratories). The background-subtracted intensities were normalized by dividing them 
by the intensity of the respective actin band. Protein expression ratios are reported as the 
average from two separate experiments. 
3.2.4 Effects of Arsenic Trioxide on Gene Expression Profiles of Human 
Megakaryocytic Leukemia Cell Lines by Microarray Analysis 
Reverse Transcription and Labeling of cDNA 
Synthesis and labeling of cDNA was carried out using the CyScribe First-Strand cDNA 
Labelling Kit. Freshly prepared total cellular RNA (10 |ig) (Section 3.2.3.1) was added to 
a reaction mixture containing anchored o ligo(dT) primer, 1 x C yScript buffer, 1 0 mM 
DTT, dUTP nucleotide mix and Cy3- or Cy5-dUTR The mixture was heated at 65 °C for 
5 minutes and then at 42 °C for 5 minutes; 100 U of CyScript reverse transcriptase was 
added and the reaction was further incubated at 42 °C for 2.5 hours. The reverse 
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transcription was stopped with EDTA (final concentration of 6.25 mM), and the residual 
RNA was degraded by the addition of NaOH (final concentration 0.5 M) and incubation 
at 65 °C for 20 minutes. The mixture was neutralized by the addition of acetic acid (final 
concentration 0.5 M), and the Cy3- and Cy5-labeled cDNA were pooled together and 
purified using an Amicon Microcon centrifugal filter unit (Millipore), and were 
resuspended in 5 (xL of RNase-free water. 
Hybridization and Wash Conditions 
The purified cDNA probes were mixed with 70 ^L of DIG Easy hybridization buffer 
(Roche Diagnostics GmbH), together with 4 ^L of 5 mg/mL yeast transfer RNA (tRNA) 
(Invitrogen) and 2 i^L of 10 mg/mL calf thymus DNA, and heated at 65 °C for 2 minutes. 
The mixture was applied onto the space sandwiched by two Human 19K Array slides, and 
incubated in a humidified hybridization chamber at 37 °C for 14 - 16 hours. Subsequently, 
the arrays were washed with 1 x SSC - 0.1 % (v/v) SDS at 50 °C with shaking for 10 
minutes for three times, followed by rinsing with 1 x SSC, also at 50 °C. Slides were spun 
dry for 3 minutes at 200 x g at room temperature in a 50 mL conical tubes (BD Falcon). 
Image Acquisition 
The arrays were read with a ScanArray 4000XL scanner (Packard Bioscience) at 5 yun 
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resolution and variable laser power and photomultiplier tube (PMT) settings to obtain 
optimum signal intensities. Individual 16-bit grayscale tag image file format (TIFF) 
images of the two fluors were obtained by scanning at 532 nm (Cy3) and 635 nm (Cy5). 
Data Analysis and Normalization 
A software suite, TM4，available from The Institute for Genomic Research (Rockville, 
MD, USA) was employed in the capturing and mining of microarray results (Saeed et aL, 
2003). The two TIFF images were imported into the Spotfmder software (version 2.2.3) 
for automatic spot identification and quality control, followed by manual inspection and 
confirmation. Raw intensity data of each experiment set were then fed into MIDAS 
(Microarray Data Analysis System, version 2.18)，which performed local background 
subtraction of each individual spot, and LOWESS (/ocally weighted scatter plot smooth) 
normalization within each array. Then all datasets were loaded simultaneously in MEV 
(MultiExperiment Viewer, version 2.2), where normalization among experiments was 
done. The processed data were then subject to an intensity filter, which excluded all genes 
that were not detected in both channels (Cy3 and Cy5). K-means/K-medians clustering 
module was used, which had been set to produce 6 clusters with the maximum number of 
iterations at 5 0 and at the E uclidean d istance of 5 0. G ene e xpression r atios (treatment 
versus control) are reported as the average values from six separate hybridizations. 
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3.2.5 Statistical Analysis 
Statistical analyses were performed with the SPSS software package (SPSS Inc., Chicago, 
IL, USA) or Microsoft Excel. Statistical differences between outcomes obtained in a 
population of leukemic cells treated with different experimental conditions were 
determined by the paired /-test. Where the assumption for normality was not met, 
Wilcoxin Sign Ranked test was applied. A P-value of 0.05 or less was assigned statistical 
significance. Data are expressed as mean 士 standard error of the mean (SEM). 
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Table 3.1 Antibodies Used in the Study. 
Flow Cytometry 
Antigen Clone Antibody Conjugation Cat. No. Origin 
Caspase-3, active Polyclonal Rabbit IgG PE 557091 BD 
form Pharmingen 
CD137 4B4-1 Mouse IgGi，K PE 555956 
Isotype control MOPC-21 Mouse IgGi.K FITC 555748 
Isotype control MOPC-21 Mouse IgGi，K PE 555749 
DR4 DJRl Mouse IgGi.K - 14-6644 eBioscience, 
DR5 DJR2-2 Mouse IgGi.K - 14-9909 San Diego, 
Fas DX2 Mouse IgGi.K FITC 11-0959 CA, USA 
Isotype control MOPC-21 Mouse IgGi.K - 14-4714 
Mouse IgG (H+L) - Ratig FITC 11-4011 
Western Blot 
Antigen Antibody Conjugation Dilution Cat. No. Origin 
Actin Mouse IgGi - 1:1000 sc-8432 Santa Cruz 
Bax Mouse IgG2b- 1:1000 sc-7480 Biotech. Inc., 
Bcl-2 Mouse IgGi - 1:1000 sc-7382 Santa Cruz, 
Mouse IgG Goat Ig HRP 1:1000 sc-2031 CA, USA 
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Table 3.2 A List of Genes Included in GEArray Q Series Human Apoptosis 
Gene Array. 
GenBank Name Description 
Bcl-2 Family 
U66879 BAD BCL2-antagonist of cell death 
AA923639 BAKl BCL2-antagonist/killer 1 
L22474 BAX BCL2-associated X protein 
M14745 BCL2 B-cell CLL/lymphoma 2 
NM—004049 BCL2A1 BCL2-related protein A1 
Z23T15 BCL2L1 BCL2-like 1 
AF032458 BCL2L11 BCL2-like 11 
U59747 BCL2L2 BCL2-like 2 
U34584 BIK BCL2-interacting killer 
Z33998 BLK B lymphoid tyrosine kinase 
AF002697 BNIP3 BCL2/adenovims ElB 19kD interacting protein 3 
AF089746 BOK BCL2-related ovarian killer 
NM一003 806 HRK hara-kiri, BCL2 interacting protein (contains only BH3 domain) 
L08246 MCLl myeloid cell leukemia sequence 1 
Caspase Recruitment Domain (CARD) Family 
NM_001160 APAFl apoptotic protease activating factor 1 
NM_013258 ASC apoptosis-associated speck-like protein containing a CARD 
NM:003921 BCLIO B-cell CLL/l)^phoma 10 
NM_006092 CARD4 caspase recruitment domain family, member 4 
AF043244 N0L3 nucleolar protein 3 (apoptosis repressor with CARD domain) 
AF078530 RIPK2 receptor-interacting serine-threonine kinase 2 
Caspase Family 
M87507 CASPl caspase-1 
U13021 CASP2 caspase-2 
NM一004346 CASP3 caspase-3 
U28014 CASP4 caspase-4 
U28015 CASP5 caspase-5 
U20537 CASP6 caspase-6 
U67320 CASP7 caspase-? 
NM一001228 CASP8 caspase-8 
U60521 CASP9 caspase-9 
U60519 CASPIO caspase-10 
NM_003723 CASPl3 caspase-13 
NM:012114 CASPl 4 caspase-14 
Cell Death-inducing DNA fragmentation factor-like Effector (CIDE) Domain Family 
NM_001279 CIDEA cell death-inducing DFFA-WYq effector a 
NM:014430 CIDEB cell death-inducing DFFA-MYq effector b 
NM_004401 DFFA DNA fragmentation factor, 45kDa, alpha polypeptide 
NM~004402 DFFB DNA fragmentation factor, 40kDa, beta polypeptide 
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Table 3.2 (Continued) 
GenBank Name Description 
Death Domain (DD) Family 
NM_003805 CRADD CASP2 and RIPKl domain containing adaptor with death 
domain 
NM—014326 DAPK2 death-associated protein kinase 2 
NMIo03824 FADD Fas {TNFRSF6)-2iSS0c\2XQ& via death domain 
NM一002468 MYD88 myeloid differentiation primary response gene (88) 
U50062 RIPKl receptor (TNFRSF)-interacting serine-threonine kinase 1 
Death Effector Domain (BED) Family 
AFl73003 BEAR bifunctional apoptosis regulator 
AF154415 CASP8AP2 CASP8 associated protein 2 
AF010127 CFLAR CASP8 and FADD-like apoptosis regulator 
NM—003 824 FADD Fas {TNFRSF6)-SiSSOci2ited via death domain 
Inhibitor of Apoptosis (lAP) Family 
NM_004536 BIRCl baculoviral lAP repeat-containing 1 
U45879 BIRC2 baculoviral lAP repeat-containing 2 (IAP-2) 
U37546 BIRCS baculoviral lAP repeat-containing 3 (IAP-1) 
NM—001167 BIRC4 baculoviral lAP repeat-containing 4 (XIAP) 
U75285 BIRC5 baculoviral lAP repeat-containing 5 (survivin) 
AF265555 BIRC6 baculoviral lAP repeat-containing 6 (apollon) 
p53 and ATM Pathway Family 
NM—000051 ATM ataxia telangiectasia mutated 
AFOl6582 CHEKl CHKl checkpoint homolog {S. pombe) 
NM_007194 CHEK2 CHK2 checkpoint homolog {S. pombe) 
NM=004507 HUSl HUSl checkpoint homolog {S. pombe) 
M66974 GADD45A growth arrest and DNA-damage-inducible, alpha 
Z12020 MDM2 transformed 3T3 cell double minute 2，p53 binding protein 
X69910 TP73L tumor protein p73-like 
L07493 RPA3 replication protein A3, 14kDa 
Ml4694 TP53 . tumor protein p53 (Li-Fraumeni syndrome) 
Tumor Necrosis Factor (TNF) Ligand Family 
D12614 LTA lymphotoxin alpha 
NM_002341 LTB lymphotoxin beta 
X01394 TNF tumor necrosis factor 
D90224 TNFSF4 OX40 ligand 
L07414 TNFSF5 CD40 ligand 
U08137 TNFSF6 Fas ligand (Apo-IL, CD95 ligand) 
L08096 TNFSF7 CD27 ligand 
L09753 TNFSF8 CD30 ligand 
U03398 TNFSF9 CD137 ligand 
U37518 TNFSFIO TNF-related apoptosis-inducing ligand (Apo-2L, TRAIL) 
AFOl9047 TNFSFll osteoprotegerin ligand 
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Table 3.2 (Continued) 
GenBank Name Description 
Tumor Necrosis Factor (TNF) Ligand Family 
AF055872 TNFSF12 Apo-3L 
NM_003808 TNFSFI3 A proliferation-inducing ligand (April) 
AF036581 TNFSF14 Herpesvirus entry mediator-ligand 
TNF Receptor (TNFR) Superfamily 
L04270 LTBR lymphotoxin beta receptor 
M33294 TNFRSFIA tumor necrosis factor receptor 1 (TNF-Rl) 
NM一001066 TNFRSFIB tumor necrosis factor receptor 2 (TNF-R2) 
X75962 TNFRSF4 OX40 
NM_001250 TNFRSF5 CD40 (NGFR) 
X63717 TNFRSF6 Fas (Apo-1, CD95) 
M63928 TNFRSF7 CD27 
NM一001243 TNFRSF8 CD30 
U03397 TNFRSF9 CD137 
U90875 TNFRSFIOA TRAIL receptor 1 (TRAIL-Rl，Apo-2, DR4) 
AF016266 TNFRSFIOB TRAIL receptor 2 (TRAIL-R2, DR5) 
AF016267 TNFRSFIOC decoy receptor 1 (TRAIL-R3, DcRl) 
AF021232 TNFRSFIOD decoy receptor 2 (TRAIL-R4, DcR2) 
U74611 TNFRSF12 Apo-3 (DR3) 
y81232 TNFRSF14 herpesvirus entry mediator 
TNFR-Associated Factor (TRAF) Family 
U59863 TANK TRAF family member-associated NF-KB activator 
NM—005658 TRAFl TNF receptor-associated factor 1 
U12597 TRAF2 TNF receptor-associated factor 2 
NM_003300 TRAF3 TNF receptor-associated factor 3 
AF082185 TRAF4 TNF receptor-associated factor 4 
AB000509 TRAF5 TNF receptor-associated factor 5 
NM一004620 TRAF6 TNF receptor-associated factor 6 
1177845 TRIP TRAP interacting protein 
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C H A P T E R 4 
E F F E C T S OF A R S E N I C TRIOXIDE ON CELL 
PROLIFERATION, A P O P T O S I S , 
M I T O C H O N D R I A L INTEGRITY AND CELL 
D I V I S I O N CYCLE P R O F I L E S OF H U M A N 
M E G A K A R Y O C Y T I C L E U K E M I A C E L L LINES 
SECTION 4.1 Introduction 
In this chapter, the effects of arsenic trioxide (ATO) on two human megakaryocytic (MK) 
leukemia cell lines, CHRF and MEG-01, were investigated. The objectives were to test if 
ATO, which has been known to be a potent drug against acute promyelocytic leukemia, 
had potent inhibitory effects on MK cells, and to determine the optimal dose of ATO and 
duration of treatment and mechanisms on cell proliferation, apoptosis, mitochondrial 
integrity and cell cycling kinetics. 
CHRF and MEG-01 cells were incubated in the absence or the presence of ATO at 
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concentrations ranging from 1 to 8 i^M for various treatment durations ( 1 - 7 2 hours). The 
kinetics of cell proliferation and viability were investigated by cell counting and trypan 
blue exclusion assay. Flow cytometry was used to quantify the following parameters: 
apoptosis by Annexin V/PI staining and active caspase-3 expression, mitochondrial 
membrane integrity by JC-1 staining, cell division cycle kinetics by PI staining of DNA 
content and BrdU labeling of S phase, and simultaneous measurement of apoptosis and 
cell cycle profile by BrdU, caspase-3 and 7-AAD staining. 
SECTION 4.2 Results 
4.2.1 Effects of Arsenic Trioxide on Proliferation Kinetics 
During the initial 24 hours of incubation, the number of viable CHRF cells in the control 
groups increased from 2 x 10^ to 5.01 ± 0.46 x 10^ /mL. CHRF cells exposed to low 
concentrations of ATO (1 and 2 fxM) also increased in their numbers, but at a reduced rate 
(P = 0.044 and 0.013，against control cultures, respectively; Figure 4.1, left panels). 
When the concentrations of ATO were raised to 6 \iM or above, cell proliferation was 
virtually eliminated and the number of viable cells slightly decreased (P < 0.01). The 
number of untreated MEG-01 cells also increased upon culture, giving 4.26 土 0.19 x 10^  
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cell/mL. Exposure to ATO slackened cell growth significantly (P < 0.01, except for the 2 
|iM group, where P = 0.058) (Figure 4.1，right panels). 
The trend observed in the first 24 hours sustained, and could still be seen at 48 and 72 
hours (Figures 4.1). Low concentrations (1 and 2 |iM) of ATO allowed CHRF and 
MEG-01 cells to grow, yet in a much slower rate (P-value range: 0.013 - 0.046 in both 
cell lines); while higher concentrations (4，6 and 8 jiM) totally abolished cell proliferation 
(尸-value range: < 0.001 - 0.032 in both cell lines). ATO at 8 |iM significantly reduced the 
number of CHRF cells (P < 0.01 compared to initial cell number) (Figure 4.1). 
4.2.2 Effects of Arsenic Trioxide on Cell Viability 
Exposure to ATO for 24 hours did not cause significant death in CHRP cells regardless of 
the dose. However, the viability dropped with the increase in ATO concentration starting 
from 48 hours, as measured by trypan blue exclusion assay. At concentrations equal to or 
greater than 4 jiM，a significant loss of viability with respect to the control group was 
observed {P = 0.047，0.048 and 0.013 for 4，6 and 8 |iM, respectively). The effect was 
more pronounced after exposing to ATO for 72 hours (P = 0.067，0.03 and 0.012 
respectively). In addition to the concentration of ATO, the treatment duration was also 
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identified to be important. At 6 i^M of ATO or above, a significant decrease of viability 
with increased duration of exposure was observed in CHRF (24 hours against 48 or 72 
hours and 48 hours against 72 hours, in all cases, P < 0.05) (Figure 4.2A). 
In M EG-01 c ells, there was a trend of d ecreasing v lability as a function of both ATO 
concentration and treatment duration (Figure 4.2B), though the viability of treated cells 
did not statistically differ from the control cultures, regardless of the ATO concentration 
and exposure time. 
4.2.3 Apoptosis-inducing Capability of Arsenic Trioxide 
4.2.3.1 Quantitation of Externalized Phosphatidylserine 
Early apoptotic cells [Aimexin V (AnV)+ PF] were increased when CHRF cells were 
treated with high (6 and 8 ^M) concentrations of ATO for 24 hours (8.28 士 0.53 % and 
10.6 土 0.95 %, P = 0.013 and 0.005 respectively, compared to 5.04 士 0.29 % in control 
cultures) (Figure 4.3A, left panels and 4.3B). Subsequently, increased Armexin V 
binding was also observed in the lower concentration, i.e. 2 jiM {P = 0.02) when CHRF 
cells were incubated in the presence of ATO for 48 hours (Figure 4.3 A, right panels and 
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4.3B). Maximum levels of early apoptosis (13.0 士 1.38 %) were noted in the highest ATO 
concentration (8 |iM)�"and together with 4 and 6 )iM groups, they all achieved statistical 
significance compared to control cultures {P < 0.01) (Figure 4.3B). Total death (Figure 
4.3C), which comprises apoptotic and necrotic cells and calculated by the summation of 
the AnV+ PF and AnV+ PI*" cell populations, was also increased in the 4，6 and 8 |xM 
groups at the 24-hour time point (P = 0.03，0.018，0.004，respectively). By 48 hours, more 
death events were observed in substantially all ATO-treated groups, as compared to the 
untreated control (P <0.01, except 4 i^M group, where P = 0.058). 
Early apoptosis in MEG-01 cells (Figure 4.4) was not increased after exposure to ATO 
for 24 hours, within the range of concentrations tested (Figure 4.4B). Total death events 
were also not affected by the ATO treatment duration the first 24 hours (Figure 4.4C). 
When MEG-01 cells were incubated with ATO for 48 hours, significant increase in the 
early apoptotic population was observed in all ATO-treated groups, with maximal value 
attained at 8 jiM (8.98 士 0.51 %) (P = 0.014 for 1 i^M, P < 0.01 for other groups versus 
control). There was also a trend of increasing total death events with time and ATO 
concentration, as dictated by PI positivity (Figure 4.4B and C). 
4.2.3.2 Quantitation of Active Caspase-3 Expression 
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ATO-induced expression of the active form of caspase-3 was determined as another 
evidence of apoptosis.- Caspase-3 was activated when CHRF cells were incubated with 4， 
6 and 8 |iM of ATO for 24 hours. The maximum up-regulation was found in cells treated 
with 8 i^M of ATO, which had 2.95 士 0.67-fold increase over the control (P = 0.049). Very 
prominent up-regulation of active caspase-3 could be observed in the 48-hour groups, 
where there was 8.80 士 1.52 fold increase in the 8 \iM group {P = 0.007, compared to 
control) (Figure 4.5). 
After 24 hours of treatment, a trend of increased activation of caspase-3 was observed in 
MEG-01 cells starting from a modest concentration of 4 i^M (P = 0.022)，to high 
concentrations (P = 0.08 and 0.021 for 6 and 8 i^M, respectively) (Figure 4.6). When the 
incubation duration was extended to 48 hours, ATO at 4，6 and 8 |xM significantly induced 
an up-regulation of active caspase-3, from 1.79 士 0.42 % in untreated controls to 10.2 士 
0.72 % in 8 i^M group (P = 0.015 for 4 n M a n d P < 0.01 for 6 and 8 ^iM), but this was not 
observed in the lower concentrations (Figure 4.6). 
4.2.4 Effects of Arsenic Trioxide on Mitochondrial Integrity 
Mitochondria dysfunction has been recognized as a key step in apoptosis. In a normal 
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functional mitochondrion, an electrochemical gradient consisting of a transmembrane 
electrical potential (A\j/m) exists. JC-1 is a membrane permeable lipophilic cation 
fluorescent indicator, which is specifically accumulated in the mitochondria due to a 
negative interior potential (Cossarizza et al.，1993; Reers et al., 1995). The accumulation 
of JC-1 drives the reversible formation of J-aggregates that causes shifts in fluorescence 
emission from green (monomeric form) to red. In control untreated MK cells (Figures 4.7 
and 4.8, 0 hr), the majority of cell population (region Rl) showed a high emission level 
of red fluorescence, indicating the presence of intact mitochondria. In the presence of 
ATO (Figures 4.7 and 4.8, right panels), more cells were found in region R3 (brighter 
green fluorescence，yet lower red fluorescence intensity), which was indicative of the 
predominance of the monomer state, implying the loss of Av}/m. Region R2 represented the 
intermediate between Rl and R3 populations. Cells in R2 and R3 had light scattering 
properties typical of apoptotic cells (Figures 4.7 and 4.8, upper panels). The exposure of 
MK cells to ATO resulted in a dramatic reduction of cell population in Rl, accompanied 
by a concomitant increase of events in R3 in a time-dependent manner. As early as after 
8-hour exposure, trends of increasing incidences of compromised An/m were observed in 
CHRF (1.40 fold) and MEG-01 (1.55 fold) cells, with respect to the control (Figures 4.7 
and 4.8). Longer exposure time essentially gave a more remarkable increase of 2.24 and 
5.01 fold in CHRF at 24 and 48 hours respectively, and 1.94 and 4.55 fold in MEG-01. 
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4.2.5 Effects of Arsenic Trioxide on Ceil Division Cycle Profiles 
Without A T O treatment, the distribution of cells in the G Q / G I , S and G2/M compartments 
was similar at all the time points tested (1’ 4，8，16，24 or 48 hours). There was no 
immediate observable effect on the distribution of CHRF and MEG-01 cells in the cell 
division cycle phases, when CHRF (Figure 4.9) or MEG-01 (Figure 4.10) cells were 
exposed to ATO for 1 hour. Starting from 4 hours, the proportion of cells in the G Q / G I 
phase began to decline (all ATO groups P < 0.05 compared to their respective controls). 
The fall in G Q / G I was accompanied by the increase in S (P-value range 0.015 - 0.020) 
and G2/M (P < 0.01 for 4 }iM and P = 0.025 for 6 ^M) in MEG-01, though the rising 
trend was not statistically significant in CHRF. As time progressed, the fall in G Q / G I and 
the rise in G2/M became more prominent {P < 0.01 in both cell lines compared to the 
respective control). In CHRF, a trend of decreasing S phase was noted at 16 hours, but 
was not observed in MEG-01. At or beyond 24 hours, both CHRF and MEG-01 saw 
diminishing G Q / G I and S phases and an accumulating G2/M. 
4.2.6 Effects of Arsenic Trioxide on Cell Cycle Kinetics by Bromodeoxyuridine 
Labeling 
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In order to visualize the kinetics of G2/M accumulation by ATO, the cell cycle passage 
was measured in a BrdU pulse-chase experiment. Immediately after the 45-minute pulse, 
BrdU-labeling was observed in early S (region R6)，mid S (region R7) and late S (region 
R8) phases (Figure 4.11A). As cells continued through the cell cycle, populations in R6 
and R7 progressively shifted to the right and re-entered into R6 (Gi/early S) with 
weakly-labeled BrdU at 4 hours (Figure 4.1 IB, left, indicated by an arrow). However, 
such re-appearance of R6 was not observed in ATO-treated cells. Instead, an increase in S 
(R4 and R7) was noted (Figure 4.11B, right). In the control culture, further progression 
of cycling cells was evidenced by dense populations of cells with strong BrdU signal in 
R6 and R8，and the group of weakly-BrdU-positive cells in R7 at 8 hours (Figure 4.11 C, 
left, indicated by an arrow). In the ATO-treated counterpart, BrdU-positive cells in R7 
and R8 remained strong in fluorescence signals, suggesting that they had not been 
dividing and were kept in S / G 2 / M phases (Figure 4.11C, right). Twenty-four hours after 
time 0，BrdU-labeled, untreated CHRF cells had traversed G2/M and re-entered into the 
next cell cycle, as demonstrated by the overall decrease in individual BrdU signal 
intensity (Figure 4.11D, left). Meanwhile, ATO caused an accumulation of cells in R8, 
particularly at the BrdU-negative and weakly positive positions, and a reduction of 
percentages of cells in R3 and R6 (Figure 4.11D, right). 
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4.2.7 Identification of Cell Cycle Specificity of Arsenic Trioxide-Induced 
Caspase-3 Activation 
CHRF was chosen as the model cell line in this part because as demonstrated in Section 
4.2.3.2，the expression of active caspase-3 in CHRF was more prominent than that in 
MEG-01 after ATO exposure for 24 hours. 
The proportion of cells with active caspase-3 expressions in control cultures was 0.64 %� 
whereas in ATO-treated CHRF cells, the percentage increased to 2.84 % [Figures 4.12A 
(I) and B (I)]. With respect to the cell cycle status, active caspase-3 expression in the 
treatment group was localized in the following manner: G Q / G I : 34.5 % (region R3), S: 
34.5 % (region R4) and G2/M: 31.0 % (region R5) [Figure 4.12B (II)]. In terms of the 
caspase-3 positivity in the specific cell cycle phase, we observed a distribution of 6.16 %, 
3 . 4 2 %, 3 . 1 9 % of cells in the G Q / G I , S and G 2/M p hases e xpressed a ctive c aspase-3， 
respectively [Figure 4.12B (II)], while the percentages in the control culture were 0.69 %, 
0.88 % and 0.77 %, respectively [Figure4.12A(II)]. Referring to the BrdU labeling 
profile [Figure 4.12B (II)]，these apoptotic cells were mostly found in regions where the 
BrdU intensity was intermediate, but not in high BrdU intensity region (marked by arrow). 
These results suggested that CHRF cells had possibly gone through at least one mitotic 
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division before caspase-3 activation took place, and that this activation occurred 
indiscriminative of the cell cycle phase. 
SECTION 4.3 Discussion 
Since the renaissance of ATO in medicinal use, many groups have extended the study of 
ATO to various malignant cell types (Table 1.1). Despite the great number of reports on 
the effects of ATO on myeloid cells, information specifically on the MK lineage was scant. 
The first ever report linking MK cell line to ATO was published by Akao et al (1998)， 
who，by performing trypan blue exclusion assay, demonstrated that the viability of 
MEG-01 fell to approximately 60 % after 5-day treatment with 1 jiM ATO. Later, Lu et al. 
(1999) published their findings on four MK cell lines, including HEL，MEG-01, M-07e 
and UT7. By morphological examination, DNA fragmentation analysis and TUNEL assay, 
these authors concluded that that ATO could significantly inhibit growth and induce 
apoptosis in the four MK lines at concentrations between 0.5 and 2 fxM. Recently, Jing et 
al. (2002) showed that caspase-3 activity was increased in ATO-treated MEG-01，but in 
contrast to the low doses reported previously, this observation was seen only at a 
concentration of 10 \xM. 
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Based on the evidence collected in this study, we supported that ATO could seriously 
hamper the growth and could induce apoptosis in MK cells, shown by the increased 
extemalization of phosphatidylserine and activation of pro-caspase-3, but only at 
concentrations equal to or above 4 |iM. We argued that, as we have illustrated in this 
chapter, the effect of 1 - 2 |iM of ATO on both CHRF and MEG-01 lines was relatively 
mild. At such concentrations, proliferation was retarded, but not abolished, and neither 
apoptotic nor total death events were significantly increased when the cells were 
incubated for 24 hours. 
To our knowledge, the anti-leukemic effects of ATO on CHRF cell line had not been 
documented. Our data suggested that MEG-01 was more resilient to ATO insult than 
CHRF, as depicted by smaller percentages in early apoptotic and late apoptotic/necrotic 
cells, as well as caspase-3 activation in MEG-01 as compared to CHRF. Interestingly, 
while CHRF showed prominent Annexin V binding at the end of 24-hour incubation, the 
extemalization of phosphatidylserine in MEG-01 did not appear until after another 24 
hours. However, the active form of caspase-3 was significantly up-regulated in both cell 
lines in 24 hours. The difference in susceptibility towards ATO between CHRF and 
MEG-01 cells might possibly be related to the origin and the degree of maturation of the 
two cell lines. The more mature CHRF was derived from a 17-month-old child, whereas 
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the less mature MEG-01 was originated from an adult aged 55. Clinical evidence has 
I 
suggested that AMKL is a biologically heterogeneous disease (Dastugue et al.’ 2002) and 
that pediatric patients generally have better outcome than the adults (Garderet et al, 
2004). However, the exact factors contributing to such difference remain unclear. 
It had been reported that arsenite could increase the permeability transition pore opening, 
which is associated with mitochondrial membrane depolarization (Petronilli et al, 1994; 
Larochette et al., 1999; Zheng et al., 2004). Zhu et al. (1999b) demonstrated 
mitochondrial damage in chronic lymphoblastic leukemia SKW-3 cells and Namalwa 
Burkitt's lymphoma cells treated with 1 and 2 i^M of ATO respectively. Similar results 
were shown later in the APL cell line NB4 (Cai et al” 2000) and several other cells of 
myeloid and lymphoid origin (Korper et al., 2004; Rojewski et al” 2004a). Here we have 
provided evidence that ATO-induced mitochondrial damage was also found in MK cell 
lines CHRF and MEG-01. Those cells with perturbed mitochondria were in fact apoptotic 
or necrotic, as depicted by their distinctive light-scattering properties. Mitochondrial 
perturbation has been suggested to be an important step in cytotoxic drug-mediated 
apoptosis (Solary et al” 2003). Given that cytochrome c and/or AIF release from 
mitochondria is usually accompanied by mitochondrial membrane depolarization in many 
cell types treated with ATO (Sordet et al., 2001; Akay and Gazitt, 2003; Michel et al., 
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2003; Karlsson et al” 2004)，we postulate that the compromised mitochondrial integrity 
by ATO might be one of the initiation steps in the induction of apoptosis in MK cells. 
Alemany and Levin (2000) observed an increased proportion of ATO-treated MEG-01 
cells in mitosis and suggested that ATO may have an effect on cell cycle. By monitoring 
the changes in cell cycle profiles, we confirmed that ATO promoted the accumulation of 
cells in the G2/M phase of the cell division cycle, and at the same time depleting the 
populations in G Q / G I and S phases. Our results were also in line with previous studies in 
human skin fibroblasts (Yih et al, 1997), myelomonocytic U937 cells (Park et al” 2001b) 
and CML K-562 blasts (Li and Broome, 1999) which suggested that ATO slowed down 
cell cycle progression by delaying mitosis (M phase). A closer examination of the cell 
cycle profiles obtained in ATO-treated CHRF and MEG-01 revealed that ATO caused a 
slight increase in S phase at 4 hours, followed by increases in both S and G2/M phases at 
8 hours. This raised the possibility that ATO might attenuate S phase progression as well. 
We thus monitored cell cycle progression by BrdU pulse-chase experiment. In untreated 
cultures, BrdU-positive cells originally in early S phase progressed to Gi/S of the next 
cycle by the end of 24 hours. However, ATO-treated cells consistently traversed S more 
slowly than control cells, shown at 4 hours, and experienced a delay in G2/M to Gi 
transition, as suggested by the smaller number of BrdU-positive cells re-populating the G\ 
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compartment and the accumulation of cells in the G2/M phase. 
The effect of ATO on MK cell cycling appeared to be different from that reported in 
MC-CAR myeloma cells harboring wildtype p53, at which cells at G! checkpoint were 
arrested accompanying an up-regulation of p21 (Liu et al., 2003). The direct involvement 
of p21 was demonstrated in report on pancreatic cells (Li et al., 2003b) after exposure to 
ATO, while in head and neck squamous cell carcinoma PCI-1 (Seol et al.，1999) and renal 
carcinoma A498 (Hyun et al., 2003), it was the binding with cyclin-dependent kinases 
that was increased instead of the up-regulation per se. Taken together, these observations 
clearly illustrate the complexity of the mechanisms by which ATO induces cell cycle 
perturbation, where differences among cell lines exist. 
Cell cycle regulation and apoptosis are two seemingly independent events, yet they are 
interconnected in many ways (Lundberg and Weinberg, 1999; Evan and Vousden, 2001). 
It has been proposed that the cell cycle position is one of the determinants of apoptosis 
(Del Bino et al.，1992; Gorczyca et al” 1993). In an APL cell line NB4 treated with ATO 
at a low dose (2 apoptosis was primarily found in cells arrest in G2, and such 
preference was lost when the concentration of ATO was raised to 8 jiM (Ma et al., 1998). 
Ling et al. reported mitotic arrest occurred prior to apoptosis in MCF-7 breast cancer cells 
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(2002). It was also shown in U937 and HL-60 cells that ATO-induced cell cycle arrest at 
early mitosis would eventually lead to apoptosis (Halicka et al.,1002). We performed 
multiparameter flow cytometry to delineate the cell cycle position of apoptotic cells. By 
combining the profiles of cell cycle, active caspase-3 staining and BrdU labeling status, 
we demonstrated the presence of apoptotic cells in all phases of cell cycle. These cells 
were found after they had traversed G2/M once. This probably explains the delay in the 
onset of apoptotic phenotype. 
In conclusion, although difference in susceptibility exists in leukemia cells of MK lineage, 
ATO at 6 p,M) was remarkably potent in inhibiting the growth of these malignant cells, by 
delaying cell cycle progression, perturbing mitochondria and inducing apoptosis. 
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Figure 4.1 ATO Inhibited the Proliferation of CHRF and MEG-01 Cells. 
(Left panel) CHRF or (right panel) MEG-01 cells were exposed to 0, 
1，2，4, 6 or 8 i^M ATO for varying lengths of time (24，48 or 72 hours). 
(A) The number of viable cells (trypan blue excluding) is plotted 
against the treatment duration. (B) The tables show the fold difference 
with respect to the initial cell number (2 x 10^  /mL). Data represent the 
mean and SEM of three separate experiments. An asterisk (*) signifies 
P < 0.05，** represents P < 0.01，when compared to the respective 
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Figure 4.2 ATO Reduced the Viability of CHRF and MEG-01 Cells. 
(A) CHRF and (B) MEG-01 cells were exposed to 0，1，2, 4，6 or 8 
|iM ATO for varying lengths of time (24，48 or 72 hours). Trypan 
blue exclusion assay was performed to enumerate both viable and 
non-viable cells. While the viability of MEG-01 remained high even 
after 72 hours of treatment, ATO exerted greater cytotoxicity to 
CHRF cells. Each point represents the mean and SEM of the results 
obtained from three independent experiments. An asterisk (*) 
signifies P < 0.05，** represents P < 0.01, when compared to 
control cultures. 
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Figure 4.3 ATO Induced Apoptosis in CHRF Cells. 
CHRF cells were cultured with 0，1，2，4，6 or 8 i^M of ATO for 24 
or 48 hours, and apoptosis was determined by flow cytometry using 
the Aimexin V method. (A) The light scattering and the staining 
profiles of Aimexin V-FITC and PI of each treatment group are 
shown in Panels I and IL The numerals in the quadrants indicate the 
percentages of cells in that particular quadrant with respect to total. 
Early apoptotic populations are found in the lower-right quadrants, 
while necrotic or late apoptotic cells are localized in the upper-right 
quadrant. (B) High concentrations of ATO (4, 6 and 8 i^M) 
up-regulated the early apoptotic phenotype in CHRF cells in 24 
hours, and lower concentration (2 |iM) became effective when 
treated for 48 hours. (C) Total cell death was significantly 
increased in the 6 and 8 i^M groups. Each point represents the mean 
and SEM of the results obtained from five independent 
experiments. An asterisk (*) signifies P < 0.05, ** represents P < 
0.01，when compared to control cultures. 
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Figure 4.4 ATO Induced Apoptosis in MEG-01 Cells. 
MEG-01 cells were cultured with 0，1，2，4，6 or 8 i^M of ATO for 
24 or 48 hours, and stained with FITC-conjugated Annexin V 
(AnV) and PI, followed by the flow cytometric analysis. (A) The 
light scattering and staining profiles of a representative experiment 
are shown in Panels I and II. Refer to Figure 4.3 for more details. 
Treating with ATO for 48 hours significantly increased the 
percentage of (B) early apoptotic and (C) total death populations in 
MEG-01 cells. This could not be observed in MEG-01 cells treated 
for a shorter duration, i.e. 24 hours. Each point represents the mean 
and SEM of the results obtained from five independent 
experiments. An asterisk (*) signifies P < 0.05，** represents P < 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































g o o . • … g _ 
Ohr • 8hr . ： • . 24.hr| : : • � ; 4 8 h ^ 
碧」 ..‘• • . . - §� ’ . .c : . : : . . i： • V：.；.., §: ••;•:.：•• 
i § � ： > . • : i § � • • • • • • i§�：�j5[,:.、： I ! �：絲; • •• 
•：••• •. • • • «。: •舉：心• & ： ” 觀 I . . . 
警 響 響 . 1 丨 复 I 1 <=> i • • • •  I o-^ .ffTTi Mil ,1 
0 200 400 600 800 1000 0 200 400 600 800 1000 0 200 400 600 800 1000 0 200 舶0 600 800 1000 
Fow«iard Scatter Forward Scatter Forward Scatter Fonvaard Scatter 
f . 譯 _ _ f : , f ; . _ 
M-RNRI., ••••••.I'.IIMHI O- .TMN' F . V L N , G - � . . , , _ ._•’-IV •• LIFGB ^  , 
1 0 。 1 0 ' 10^  103 lo" 10。10l 102 103 lo^  10。10^  10^  10^  1 0 均 li' To^  10^  
JC-1 (Green Fluorescence) JC-1 (Green Fluorescence) JC-1 (Green Fluorescence) JC-1 (Green Fluor«sc«nce) 
(B) 
S 30 n * 0 * 
S 25 T 
^ 20 齒 
\ 15 國 
1 10 * I N 
: 5 J H ^ H 
^ 0 
0 8 24 48 
Treatment Duration (hr) 
Figure 4.7 ATO Induced Mitochondrial Damage in CHRF Cells. 
CHRF cells were cultured with 0 o r 6 ^ M of ATO for 8, 24 or 48 hours, 
and were stained with JC-1 for the visualization of A\^ rn by flow 
cytometry. (A) After ATO treatment, depolarization of A\\fm became 
evident as indicated by increased cell population in R3. Cells found in 
regions R2 (in red) and R3 (in blue) had light scattering properties 
typical of apoptosis. (B) The mean and SEM of the results were 
obtained from three independent experiments. Mitochondrial damage 
was most marked at 24 and 48 hours post ATO treatment. An asterisk 
(*) signifies P < 0.05, when compared to control cultures (0 hr). 
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Figure 4.8 ATO Induced Mitochondrial Damage in MEG-01 Cells. 
MEG-01 cells were cultured with 0 or 6 i^M of ATO for 8, 24 or 48 
hours，and were stained with JC-1 for the visualization of Avi/m by flow 
cytometry. (A) After ATO treatment, depolarization of Avj/m became 
evident as indicated by increased cell population in R3. Cells found in 
regions R2 (in red) and R3 (in blue) had light scattering properties 
typical of apoptosis. (B) The mean and SEM of the results were 
obtained from three independent experiments. Mitochondrial damage 
was most marked at 24 and 48 hours post ATO treatment. An asterisk 
(*) signifies P < 0.05, when compared to control cultures (0 hr). 
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Figures 4.9-4.10 ATO Gradually Arrested CHRF and MEG-01 in Gz/M, with the 
Concomitant Decrease in GQ/GI and S Populations. 
CHRF or MEG-01 cells were treated with 0，4，6 or 8 i^M of ATO for 
various durations. (A) Histograms demonstrate cell number versus 
DNA content of viable cells in different groups as indicated. (B) The 
proportion of cells in each of the three phases of the cell cycle was 
determined by ModFit LT. Data represent the mean and SEM of the 
results obtained from at least three independent experiments. An 
asterisk (*) signifies P < 0.05, ** represents P < 0.01，when 
compared to 0 i^M group at the same time point.. 
86 
(A) a Go/Gi • S • G2/M 
hr j O^M ” . 6 ^M ^ 8 ^M 
- I 1 j 
I 秀i I I I p-l I 
i 1 , 1 1 1 1 1 J m i i i , , , ,11111,»,1111,1 j ,111 ,1 ,MrI I , ,1 , , ^ M 
0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 
Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) Channels {FL2-A-FL2-Area) 
Uhr j ^ 
"i I h 1 I i" 
§ I IJi I IJi I IJi I 
11,111, o]1,1,1,,M111,,11,：彳1,1 I I , , M 1 1 , , I" M 
0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 
Channels (FL2-A-FL2-Area) Channels (FL2-A-FI_2-Area) Channels (FL2-A-FL2-Area) Channete (FL2-A-FL2-Area) 
J I J Jj 丨 i 
J M j M M :i M 
0 2 0 0 3 0 0 4 0 0 5 0 0 0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 0 1 M 2(^0 3 ^ 0 4 ^ ) s i o 
Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) Channels (FI_2-A-FL2-Area) Channels (FL2-A-FL2-Area) 
Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) 
I si I gi 1 gi 
- - . M - r 德 1；^, 
Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) 
Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) Figure 4.9 ATO Arrested CHRF Cells in G2/M. 
87a 
JB) 
Gfl/Gi 1 hour 4 hours 8 hours 16 hours 24 hours 48 hours 
OnM 39.1 士 1.03 39.4 士 0.65 38.2 士 0.34 36.8 士 0.47 36.3 士 1.28 37.6 士 1.24 
4 n M 39.0 土 0.68 34.1 士 0.82 28.5 士 0.56 22.6 ±0.29 31.5 士 1.06 23.3 土 0.94 
* 氺 * * * 氺 * 氺氺 
6)iM 39.9 土 1.28 34.3 士 0.61 27.6 士 0.15 20.4 ± 0.63 23.4 士 0.53 17.9 士 1.45 
氺氺 * * * * * * 本本 
SjiM 38.7 士 0.99 34.0 士 1.33 30.3 ± 0.83 22.7 士 0.25 19.6 士 1.21 13.2 士 1.37 
* * * * * * * 本 
S 1 hour 4 hours 8 hours 16 hours 24 hours 48 hours 
OpM 49.6 土 0.98 48.2 士 0.51 48.5 士 0.24 49.7 士 0.14 50.2 士 1.50 48.8 土 1.80 
4 n M 49.6 土 1.04 54.2 士 2.44 53.4 士 2.44 45.8 士 1.75 35.4 士 1.80 43.0 士 2.00 
* * * 
6]iM 50.4 士 0.46 53.2 士 2.07 53.8 土 1.85 47.2 ± 0.86 35.3 土 0.67 38.9 土 1.24 
* * * * 
S\iM 51.0 士 0.92 54.7 士 1.93 53.4 土 1.71 47.4 ±0.94 39.7 士 0.40 40.1 士 2.07 
* * * 
Gi/M 1 hour 4 hours 8 hours 16 hours 24 hours 48 hours 
O j i M 1 1 . 3 土 1.33 12.4 士 1.03 13.3 士 0.11 14.2 ±0.73 13.5 士 0.38 13.6 士 1.01 
4 j i M 11.4士1.35 11.7 士 2.50 18.2 士 1.93 31.6士 1.64 33.1 士 1.75 33.7 土 1.41 
氺 * * 氺 * * 
6fiM 9.9 士 1.50 12.5 土 2.22 18.7 ± 1.77 32.4 土 0.76 41.3 士 1.16 43.2 土 1.41 
* * * * * * 
8jiM 10.4士 1.56 11.4±1.55 16.2士2.51 29.9士 0.70 40.7士 1.12 46.7土 1.53 
* * * * * * 





30 fc l U 輪 
20 - I 卞 . 
1: | | | |_ 川 _ 川 i t f j l l t f � 
0 4 6 8 
[ATO] (mM) 
6 0 -1 
50 - n ^ T m rWk * r t h 
40 濯 ^ ^^  I 
法30 “ 
； ； 川 1 _ 1 _ 川 _ 隱 
0 4 6 8 
[ATO] (|JM) 
(III) G2/M 
50 n ** 
* * Jl, * * 
口 1 hour 40 - 广 
• 4 hours 30 n 广 产 
• 8 hours 20 x 
口 16 hours 10 - n ^ f t t n i l l f f 幽 J l 
口 24 hours 0 丄I I I _ I I I I • I I N • t i l l M i ^ 
• 48 hours 
0 4 6 8 
[ATO] (mM) Figure 4.9 ATO Arrested CHRF Cells in G2/M. 
87c 
(A) El Go/Gi • S • G2/M 
j l hr I 0 ^M j I 4 i^M j 1 6 ^M j i 8 ^M 
I I I I I r I r 
！I, J M L „ ：丨.…I,,JM.,^ , 
0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 6 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 6 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 
Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) U hr i i i i ^ , f h I I h • I- F I F I F I 
银 1 I 银 i 银 I 
D ^ J T O ^ ！J M ； 
0 1 0 0 2 0 0 3 6 0 4 0 0 5 0 0 0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 -0 1 0 0 2 0 0 3(X) 4(W S M 
Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) Channete (FL2-A-FL2-Area) hr 1 i ^ i 
€ i t I t 丨 f 1 
® 1 丨丨彳 L C Lii ® La 
0 1 6 0 2 0 0 3 0 0 4 0 0 5 0 0 0 1 0 0 2(X) 3 0 0 4 0 0 5 0 0 0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 0 1 0 0 2(X) 3(X) 4 0 0 5 0 0 
Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) 
1 1 i I ：] I 
： 彳 職 ; T ： 彳 纖 I I I II,, 
0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 0 1 0 0 2 0 0 3 0 0 4 0 0 S O ) 0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 0 1 6 0 2 0 0 3 0 0 4 0 0 5 0 0 
Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) 
卞 4 h r j I j j 
! 1 U ! a i U 
6 160 2 6 0 3 0 0 - 4 0 0 5 0 0 6 100 200 3 0 0 4 0 0 600 0 100 2(k) 3 6 0 4(X) 0 1 0 0 2 0 0 3 0 0 400 600 
Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) 
隐 I M i i 
6 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 0 1 0 0 2 0 0 3 0 0 4 0 0 6 0 0 0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 0 1 6 0 2 0 0 3 0 0 4 0 0 5 0 0 
Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) Channels (FL2-A-FL2-Area) Figure 4.10 ATO Arrested MEG-01 Cells in G2/M. 
88a • 
JB) 
Go/Gi 1 hour 4 hours 8 hours 16 hours 24 hours 48 hours 
O ^ i M 4 4 . 4 ± 1.45 46.1 ±0.91 46.1 ± 1.51 44.1 ± 1.32 45.4 ±0.70 48.5 ±0.75 
4\iM 4 3 . 8 士 1 . 1 6 3 9 . 1 土 1 . 1 7 2 9 . 9 士 0 . 2 1 2 9 . 3 士 0 . 8 3 4 1 . 4 ± 2 . 0 1 3 2 . 0 士 1 . 3 9 
* * * * * * 本氺 
6]iM 43.2 ±0.12 40.8 土 0.14 30.2 土 1.98 27.1 士 0.58 30.4 ± 1.99 25.8 士 1.56 
* 氺 * 氺 * 氺 * * 本 
S]iM 44.4 土 0.45 39.8 士 1.28 31.1 士 2.05 27.8 士 0.61 26.1 ±2.00 23.0 士 1.93 
* * * * * * 氺氺 
S 1 hour 4 hours 8 hours 16 hours 24 hours 48 hours 
OjiM 42.2 土 0.59 40.3 士 0.99 40.7 士 0.29 41.2 士 2.04 40.2 ±0.34 38.1 士 1.18 
4 n M 41.7 士 0.61 43.7 士 1.40 49.5 士 1.30 37.8 士 2.09 25.4 士 0.78 32.6 士 1.97 ** * * * * * * * 
6fiM 44.5 士 0.41 43.1 ±0.60 47.7 士 2.55 43.4 土 2.64 26.7 士 1.87 27.9 士 2.27 
* * * 
8jiM 41.6 士 0.13 44.4 土 0.40 45.8 土 2.48 46.9 士 2.63 33.5 士 1.87 21.8 ±1.41 
* * * * * * 
G2/M 1 hour 4 hours 8 hours 16 hours 24 hours 48 hours 
O n M 1 3 . 5 士 0.86 13.5 士 0.08 13.1 土 1.21 14.7 士 1.16 14.5 ±0.59 13.4 ±0.48 
4 n M 14.6 士 0.55 17.2 士 0.23 20.6 士 1.08 32.9 士 1.63 33.3 士 2.12 35.4 士 2.31 
* * * * * * 氺氺 
6nM 12.3 士 0.53 16.1 士 0.46 22.1 士 0.57 29.6 士 2.33 42.9 土 2.00 46.3 士 3.57 
氺 * * * * * 
8nM 14.0 ±0.58 15.8 士.0.88 23.1 士 0.43 25.3 ±2.70 40.4 ±1.50 55.2 士 3.15 
* ** ** 
Figure 4.10 ATO Arrested MEG-01 Cells in G2/M. 
88b 
(B) 
(I) Go/Gi 50 n ^ 
4 0 广 � � " n ^ f i r & i r g 
1 ii；*. ^ ** 
咨 n M n 
2 0 - �i I I I I I 
1:训_川_川_11丨_| 
0 4 6 8 
[ATO] (mM) 
(II) S * 
5 0 ] i n ^ iJ^ 
40 - r w f ^ r i ^ . r i 1 r f * 
30 麵 ^ 
20 ^ 
0 4 6 8 
[ATO] (mM) 
(III) G2/M 60 -j ** 
• 1 hour � 闭 ** 
n 4 hours 广 
• 8 hours � * ； 
20 - * 广 i, , ； 
口 i6hours 10 - r r r f m r f 咖 r f i l l r f _垂 
° 24 hours a 1 I I I 吸 I I I • , I 丨丨 • i I M • 丨 • 48 hours ^ 
0 4 6 8 
[ATO] ( _ ) 
Figure 4.10 ATO Arrested MEG-01 Cells in G2/M. 
88c 
㈧ I , ^ 
a 200 «)0D BOO 8D0 1000 lo" lo^  10�lO�10片 y . .'灣：'，'...-:.;‘ ForwtnlScttter BrdU4=ITC £f~�_ ' •p .':•'�. I ,. , g m : 
gi V.-.--./ si 1 
s i ^ 雜.妄;：I > _ 磁 ： 
堪 j _ : 、 ’ ： y m ： ： ^ 
氣 . � . . 0 200 � 0 60  BOO 1D00 0 200 400 bOO BOO 1QD0 " 0 ' ' ' "200' • • '<l6o' • _ 'bOo' ‘ • BOo' ‘ • 1000 7^AD-Width 7-AAD 
Figure 4.11 ATO Slowed Down Cell Cycle Progression of CHRF Cells. 
CHRF cells were pulse-labeled with BrdU for 45 minutes and harvested 
after treatment with or without 6 i^M of ATO for 0，4，8 or 24 hours as 
indicated in the cytograms (A - D). Bivariate analyses of BrdU 
incorporation and DNA content were performed by flow cytometry. 
Gating strategy was shown. Only those cells within regions Rl and R2 
were included in the BrdU-7-AAD bivariate plot. Cells in regions R3, 
R4 and R5 were non-BrdU labeled G Q / G I , S and G2/M populations, 
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Figure 4.12 ATO Induced the Activation of Caspase-3 in All Phases of the Cell 
Cycle. 
CHRF cells were treated with or without ATO for 24 hours. After 
permeabilization, the cells were stained with anti-active caspase-3 and 
7-AAD. In another experiment, CHRF cells were pulse-labeled with 
BrdU for 45 minutes and harvested after treatment with or without 6 
^M of ATO for 24 hours. The cells were finally stained with anti-BrdU, 
anti-active caspase-3 and 7-AAD before analyzed by flow cytometry. 
(A) (I) Baseline active caspase-3 expression in control culture. The 
regions R4，R5 and R6 represent G Q / G I , S and G 2 / M phases, 
respectively. (II) Active caspase-3 expression with respect to each cell 
cycle phase, from left to right: G Q / G I , S and G 2 / M . (B) (I) and (II) 
.. Significant increase in active caspase-3-positive nuclei in ATO-treated 
CHRF. The respective BrdU labeling status is shown in (II). Those 
cells that had high BrdU fluorescence intensities had relatively fewer 
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C H A P T E R 5 
E F F E C T S OF A R S E N I C T R I O X I D E ON 
A P O P T O T I C SIGNAL E X P R E S S I O N IN H U M A N 
M E G A K A R Y O C Y T I C L E U K E M I A C E L L LINES 
SECTION 5.1 Introduction 
-Except in APL cell lines, signals involved in the process of ATO-induced apoptosis are 
largely unknown. In Chapter 4，we have demonstrated that CHRF and MEG-01 cells are 
responsive to ATO apoptotic insults. In this chapter we investigate ftirther the signals that 
might play a role in transducing apoptosis. 
The expression profiles of regulatory genes associated with apoptosis in ATO-treated 
CHRF and MEG-01 cells were studied by a cDNA expression array comprising of 106 
genes from 11 families (Table 3.1). In order to assess the upstream gene expression 
events, and to avoid the interference by cellular degradation in the late stage of apoptosis, 
earlier time points were selected. Following exposure to 6 |iM of ATO for 4, 8 or 16 hours, 
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total cellular RNA extracted from CHRF or MEG-01 cells was reversed transcribed, 
biotin-labeled and hybridized on a GEArray Q series human apoptosis array. Individual 
spot intensity was subtracted for background and normalized to the internal control. The 
mRNA expression of ATO-treated cells was compared to that of untreated control cells to 
give a relative expression ratio. 
Regulation at the protein level was investigated after CHRF and MEG-01 cells were 
incubated in the absence or the presence of ATO (6 |xM) for various treatment durations 
(4 - 48 hours). Antigens on the cell surface, including Fas, CD137 and DR4/5 were 
analyzed by flow cytometry, while intracellular proteins, Bax and Bcl-2, were studied by 
Western blots. 
SECTION 5.2 Results 
5.2.1 Effects of Arsenic Trioxide on mRNA Expression Levels of Apoptotic 
Regulators 
Four representative GEArray human apoptosis array images (two for each cell line) are 
shown in Figure 5.1. Each gene on the array was printed in a tetraspot format. 
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Peptidylprolyl isomerase A (N1 - 4; Figure 5.1) was chosen as the housekeeping gene 
and the averaged intensity of the quadraplicate was used for normalization of each gene. 
The exclusion criteria were set such that genes having spot diameter of 0, or having 
intensity less than 0 after background subtraction were ignored in further analysis. Of the 
96 target genes tested, the expression of 38 - 42 were detected in each hybridization 
(CHRF or MEG-01). Expression profiles of ATO-treated CHRF and MEG-01 cells at 4，8 
and 16 hours are presented in Figures 5.2A and 5.3A, respectively. The identification of 
genes affected by ATO exposure was based on expression changes that were at least 
2-fold up- or down-regulated in at least one time point. Genes that met the requirements 
-were listed in Table 5.1. 
The gene expression profile of ATO-treated MEG-01 appeared to be different from that of 
CHRF cells and that more genes were differentially expressed in response to ATO in 
MEG-01 than in CHRF cells, particularly those with significant up-regulations (8 in 
MEG-01 versus 2 in CHRF) (Table 5.1). Significantly up-regulated genes in MEG-01 
included 乂TM，CASPl, CASP2, CASP5, CASP8, CFLAR, CRADD and TNFRSF6. On the 
other hand, in CHRF cells, CASPl and TNFRSF9 were the only two genes showing 
significant increase in mRNA expression. A trend of diminishing MCLl expression was 
the common observation in CHRF or MEG-01 cells exposed to ATO, but the magnitude 
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of decrease was more prominent in the latter. Some other genes {ATM, BCLIO, HUSl and 
RPA3) had significant reduction in expression at certain time points in CHRF, but they 
were not observed in MEG-01. 
5.2.2 Effects of Arsenic Trioxide on Protein Expression Levels of Apoptotic 
Regulators 
5.2.2.1 Flow Cytometric Analysis 
"Fas 
Baseline expression of Fas was detected in both cell lines (mean fluorescence intensity 
[MFI] 19.9 士 0.62 in CHRF and 22.8 士 1.11 in MEG-01) (Figures 5.4 and 5.5). A trend 
of up-regulation was observed as a function of treatment duration. Initially, the effect of 
4-hour ATO exposure on Fas expression was minimal; with 1.11 士 0.01 fold in CHRF and 
1.09 土 0.03 fold in MEG-01, respectively as compared to untreated controls (i.e. 0 hour). 
At 48 hours, the fold-increase of Fas expression had reached 1.96 土 0.20 in CHRF and 




Cell surface expression of CD 137 protein was undetectable in unstimulated CHRF and 
MEG-01 cells as the MFI of these cells stained with IgG isotype and anti-CD 137 
antibodies did not differ from each other. The presence of ATO significantly induced a 
consistent and mild expression of CD 137 in a time-dependent fashion. Increases from 
1.20 土 0.04 and 1.21 士 0.03 fold of control (0 hour) at 4 hours, to up to 1.76 土 0.03 and 
1.68 士 0.11 fold at 48 hours (both P < 0.001) were recorded in CHRF and MEG-01 cells, 
respectively (Figures 5.6 and 5.7). 
-Death Receptors (DR) 4 and DR5 
When compared to cells stained with isotype antibodies (open histograms; Figures 5.8A 
and 5.9A), untreated CHRF and MEG-01 cells exhibited a low level of surface DR4 
expression (closed histograms in gray). However, when the cells were treated with ATO 
for 48 hours, there was a trend of reduction of DR4 surface protein level as demonstrated 
by a left-shift of the histogram (closed, in violet), almost superimposing the isotype 
control (Figures 5.8A and 5.9A). In terms of fold changes, DR4 expressions in 
ATO-treated CHRF and MEG-01 cells were 0.75 土 0.05 fold, and 0.67 士 0.03 fold of 
control, respectively. In control cultures, DR5 expression was undetectable. In response to 
ATO exposure, a slight increase in the DR5 expression level was observed (1.26 士 0.13 
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fold in CHRF, 1.25 士 0.11 fold in MEG-01, over control) (Figures 5.8 and 5.9). 
5.2.2.2 Western Blot Analysis 
In Chapter 4，we have demonstrated the depolarization of mitochondrial membrane 
potential, indicating an operational intrinsic apoptotic pathway. We thus went on to 
determine the protein levels of two keynote members of the Bcl-2 family, pro-apoptotic 
Bax and anti-apoptotic Bcl-2, during the course of ATO exposure. Bax and Bcl-2 protein 
expressions were present in both CHRF and MEG-01 cells in control cultures (Figure 
'5.1 OA). Upon exposure to ATO, Bax expression in MEG-01 increased progressively with 
time. Similar observation was found in CHRF, although the rising trend was interrupted at 
24 hours (Figures 5.10B and C). The effect of ATO on Bcl-2 level in CHRF was 
prominent. A time-dependent decline was readily observed in 24 hours. In MEG-01, the 
level of Bcl-2 expression remained relatively constant throughout the experimental time 
frame (Figures 5.1 OB and C). Nevertheless, Bax to Bcl-2 ratios went up in the course of 
time in both cells. Within 24 hours, the ratio went up from 0.63 士 0.08 to 2.65 士 0.68 in 
CHRF, and from 0.70 士 0.15 to 1.10 土 0.41 in MEG-01 (Figure 5.10D). 
SECTION 5.3 Discussion 
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Apoptosis is a complex process that is tightly coordinated by a repertoire of mediators 
and regulators. Multiple pro- and anti-apoptotic pathways exist and are differentially 
acted upon by chemotherapeutic agents so as to shift the balance to the apoptotic side. 
The pattern of interplay of these pathways is usually dictated by cell type and stimulus, 
such that a generalized model may suit well in one cell, but may not fit into another. ATO 
was first applied clinically to the treatment of APL, thus the cancerous cell lines derived 
from it were most well studied. Alemany and Levin (2000), based largely on the 
knowledge in NB4 cells, extrapolated the mechanisms to MK, but so far apart from the 
diminution of Bcl-2 (Lu et al., 1999) and the activation of caspase-3 (Jing et al., 2002), 
‘how ATO induced apoptosis in MK cells remains unclear. 
We have already demonstrated the apoptosis-inducing capability of ATO on MK cell lines 
CHRF and MEG-01. In order to shed light on the transduction of apoptotic signals 
induced by ATO, we utilized a focused cDNA microarray, which allows the simultaneous 
analysis of a number of genes associated with specific apoptotic pathways in a rapid and 
efficient fashion. By this approach, we aimed to screen and identify target pathways 
responsive to ATO in MK cells, which have not been reported previously. 
Common to both CHRF and MEG-01 cells were the significant up-regulations of CASPl 
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(caspase-1), and trends of increasing expression of TNFRSF6 (Fas) and TNFRSF9 
(CD 137) and decreasing MCLl (Mcl-l) expression. However, differences in the overall 
apoptotic regulator gene expression profile between the two MK cell lines were also 
observed. Members of the caspase family, caspase-2, -5 and -8 mRNA were consistently 
and exclusively up-regulated in MEG-01 cells. On the contrary, expression of ATM’ 
BCLIO, HUSl and RPA3 genes, found in CHRF, were generally down-regulated at early 
time points (4 and 8 hours) and returned to levels similar to the control at 16 hours. 
Taking into account that the changes in mRNA expression need not necessarily imply 
-corresponding changes in protein expression, and that transcriptional control is only one 
of the components orchestrating the apoptotic machinery, we also analyzed the genes at 
their protein levels. By flow cytometry, we confirmed that surface Fas {TNFRSF6) and 
CD 137 {TNFRSF9) proteins in both cell lines were increased by ATO treatment. The 
mRNA expression of DR4 (TNFRSFIOA) showed signs of reduction (0.64，0.79，0.80 in 
CHRF; 0.82，0.52，0.59 in MEG-01 at 4, 8 and 16 hours, respectively), similar trends of 
decreasing expression in DR4 protein in both cell lines were also observed. Both mRNA 
and protein expression levels of DR5 (TNFRSFIOB) were not changed significantly. The 
expression of Bcl-2 mRNA was basically below the detection threshold in our array 
system; nevertheless, we were able to show a reduced Bcl-2 protein level in CHRF. Bax 
98a 
did not show signs of changes in the cDNA microarray, however, there was a trend of 
up-regulation at the "protein level, as demonstrated by immunoblotting. The ratios of 
Bax/Bcl-2 were increased in both CHRF and MEG-01 cells, indicating a mechanism 
towards pro-apoptosis. 
Caspase-1 is the first member of the cysteine protease family, a key player in apoptotic 
cell death, but the subset to which caspase-1 belongs is much better known by its role in 
the inflammatory response (Martinon and Tschopp, 2004). The information on the 
induction of caspase-1 in vitro in response to ATO is lacking. However, an in vivo study 
"on 129/Sv mice treated with arsenicals has demonstrated an increase in caspase-1 protein 
expression in the liver (Liu et al., 2001). In another report, caspase-1 was shown to be 
activated in bone marrow mononuclear cells from APL patients on ATO therapy, as 
suggested by an increase in plO cleaved fragment in the immunoblot (Soignet et al., 
1998). Nevertheless, the significance of caspase-1 up-regulation and activation on 
ATO-induced apoptosis is not clear, since Huang et al. (1999) demonstrated that specific 
caspase-1 inhibitor could not prevent ATO-treated NB4 and HL-60 cells from apoptosis. 
Other than caspase-1, caspase-2, -5 and -8 on mRNA expressions were found to be 
up-regulated in MEG-01. Caspase-2 was originally demonstrated to be linked with the 
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adaptor molecule CRADD in the extrinsic pathway (Duan and Dixit, 1997). Later, it was 
suggested to be the apical caspase in the cell stress-induced apoptosis (Guo et al., 2002) 
and its role in chemotherapeutic drug-induced cell death was becoming increasingly 
evident (Robertson et al., 2002). Soignet et al. (1998) observed an up-regulation and 
activation of caspase-2 in the bone marrow mononuclear cells from APL patients on ATO 
therapy. We showed in the microarray study that caspase-2 and CRADD mRNA levels in 
MEG-01 cells were increased, and that mitochondrial integrity was lost in the presence of 
ATO, implying a possible function of caspase-2 in linking up the extrinsic and intrinsic 
pathways. Caspase-5 is the less well-studied member, which has been mostly described as 
an inflammatory caspase (Degterev et al” 2003). So far, they have not been mentioned in 
any of the ATO studies. On the other hand, caspase-8 is related to the extrinsic pathway. 
Fas (CD95 or Apo-1) (Walczak and Krammer, 2000) is a prominent member of the 
pleiotropic tumor necrosis factor (TNF) receptor superfamily (Aggarwal, 2003). Fas is a 
particularly well studied death receptor (Peter and Krammer, 2003) because it is an 
integral component of the death-inducing signaling complex (DISC) which is involved in 
the "extrinsic" or death receptor pathway (Curtin and Cotter, 2003; Thorbum, 2004). In 
HL-60, K-562 and RL (non-Hodgkin's lymphoma B) cell lines, ATO up-regulated the 
protein expression of Fas and its ligand. Furthermore, a Fas-blocking antibody or a 
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pan-caspase inhibitor (caspase-8 is a component of DISC) could partially suppress 
ATO-induced apoptosis (Zhu et al.，2003a). This was supported by a study on primary 
keratinocytes, which showed similar results (Liao et al, 2004). However, in a T-cell 
system, antagonistic antibody against Fas could not block cell death in the presence of 
ATO (Ishitsuka et al” 2002). The expression of Fas mRNA and protein was not affected 
by ATO in RMA, a mouse T-cell lymphoma cell line (Zhu et al” 2002). To further 
complicate the issue, ATO could activate caspase-8 in the absence of Fas in NB4 cells 
(Kitamura et al.，2000). Taken together, these studies suggest that the role of Fas in 
ATO-induced apoptosis is cell-type dependent. We have demonstrated that ATO 
“up-regulated the TNFRSF6 gene, as well as surface Fas protein expression in CHRF and 
MEG-01. Given that caspase-8 mRNA was also increased in MEG-01, we speculate that 
the Fas pathway is likely to be involved in ATO-induced apoptosis of MEG-01. However, 
as Fas can also be transactivated by p53 (Vousden and Lu, 2002), whether its 
up-regulation would directly lead to apoptosis, or just a secondary effect could only be 
clarified by further investigation. 
TRAIL (INF-互elated ^poptosis-/nducing Ligand) is structurally and functionally similar 
to its relatives, Fas ligand and the TNF superfamily (MacFarlane, 2003). Two receptors, 
DR4 (death receptor 4 or TRAIL-Rl) and DR5 (TRAIL-R2) and three non-signaling 
101a 
competitors of the receptors, also called decoy receptors DcRl, DcR2 and osteoprotegerin 
have been discovered so far (Bhardwaj and Aggarwal，2003). In parallel with Fas, DISC 
is also formed upon ligand binding (though slightly differs in the adaptor component), 
which activates caspase-8 or caspase-10, thereby initiating the caspase cascade (LeBlanc 
and Ashkenazi, 2003). It has been shown that the TRAIL pathway is another target of 
ATO-mediated action. In multiple myeloma cells treated with 4 |iM of ATO for 6 hours, 
the expression of DR4 and DR5 was increased, DcRl and DcR2 was decreased (Liu et al.’ 
2003). In line with these studies, we observed a slight induction of surface DR5 by ATO. 
However, DR4 expression was diminished, at both mRNA and protein level. Moreover, in 
“MEG-01, the DcR2 mRNA expression seemed to be increased. More evidence is required 
to account for the differential regulation of DR4 and DR5 and their decoy counterparts. 
CD137 (4-IBB or ILA, /nduced by Lymphocyte Activation) (Schwarz et al.’ 1997) is a 
member of the TNF receptor family with death domains (DD) in the intracellular region 
(Locksley et al” 2001). CD 137 is mainly found on activated T-lymphocytes, which 
functions as a costimulatory molecule (Croft, 2003), but accumulating evidence has 
suggested that CD137 is also expressed in other cell types, including monocytes (Kienzle 
and von Kempis, 2000), astrocytes (Reali et al., 2003) and blood vessel endothelial cells 
(Broil et al., 2001). Functions other than T-cell signaling have also been documented. In 
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neutrophils and eosinophils, models have been postulated that CD 137 is a negative 
regulator of inflammation by counteracting anti-apoptotic signals exerted by interleukin 
(IL)-3，IL-5 and granulocyte macrophage colony-stimulating factor (Simon, 2001). 
Michel et al. (1999) showed that immobilized CD137 could induce apoptosis in T and B 
lymphocytes and such was independent of Fas signaling, though Fas was also 
up-regulated by CD 137. To our knowledge, this is the first evidence that ATO could 
induce CD 137. Recently, CD 137 was discovered to be induced in normal lymphocytes in 
the presence of doxorubicin, bleomycin, mitomycin C and y-irradiation, which all known 
to be DNA-damaging (Kim et al.’ 2002). In another study, treatment of HeLa cells 
-over-expressing thyroid hormone receptor (HeLaTR) with triiodothyronine significantly 
up-regulated CD137 mRNA (Yamada-Okabe et al., 2003). In the same report, these 
authors also showed that CD 137 ligand could stimulate caspase activation in 
CD 137-transfected, triiodothyronine -treated HeLaTR cells. Since ATO is also known to 
induce DNA oxidative damage (Schwerdtle et al, 2003) and inhibit the DNA repair 
system (Hartwig et al., 2003)，and that ATO-induced apoptosis is usually a consequence 
of increase in ROS and caspase activation (Chen et al., 1998; Gupta et al” 2003)，CD137 
may have a role in the apoptosis of MK leukemic cells. However, the detailed mechanism 
is yet to be determined. 
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Bcl-2 and Bax are representatives of a clan of anti- and pro-apoptotic regulators. These 
antagonistic relatives are reported to participate in the regulation of intrinsic, or stress 
pathway of apoptosis, originating from the mitochondria (Larochette et al., 1999; Festjens 
et al” 2004). Reciprocal regulation of Bax (increased) and Bcl-2 (decreased) levels by 
ATO was observed in mouse T lymphocytes (Hossain et ai, 2003) and neuroblastoma 
cells (Ora et al., 2000). In this chapter, we have presented that ATO increased the 
expression of Bax protein in MEG-01 and CHRF, and decreased Bcl-2 in CHRF cells. 
The ratio of Bax/Bcl-2 has been proposed as an indicator of the susceptibility to apoptosis 
and in clinical prognosis of AML patients (MO and Ml classes) (Del Poeta et al., 2003). 
'Our data on Bax/Bcl-2 ratio showed a rising trend, which is another evidence of the 
effectiveness of ATO in the apoptotic killing of MK leukemic cells. 
Myeloid cell leukemia sequence 1 (Mcl-l) is an anti-apoptotic member of the Bcl-2 
family (Zhou et al.’ 1997) and was discovered in a differentiating myeloblastic leukemia 
cell line stimulated with phorbol ester (Kozopas et al.’ 1993). Recent studies have 
suggested that the inhibition of Mcl-l synthesis by antisense oligonucleotide significantly 
hampered the survival of multiple myeloma cells (Derenne et al., 2002; Zhang et al, 
2002). In the presence of 6.25 \xM of ATO, Mcl-l protein expressions in two pancreatic 
cell lines were time-dependently decreased (Li et al., 2003b). We have demonstrated 
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reduced Mcl-l mRNA expression levels in CHRF and MEG-01 in the cDNA microarray 
assay. It might be possible that the down-regulation of either Mcl-l or Bcl-2 (or both), 
and the up-regulation of Bax contribute to the mitochondrial pathway of apoptosis. 
The mRNA and protein expression profiles of CHRF and MEG-01 cells suggested that 
ATO-mediated apoptotic signaling was a complex array of events. We were clearly 
cautious that transcriptional control is only one but many means by which apoptosis is 
regulated. Therefore the increase or decrease in gene expressions could merely be a rough 
estimation of the pathway(s) involved. Furthermore, as the hybridizations of all genes 
"were done simultaneously, the need of specific condition for each gene was compromised, 
such that many genes, e.g. the TNF superfamily，fell out of the detection sensitivity range. 
Thus, in order to better study apoptosis, the protein levels and activation status should 
also be monitored. We were also aware that nuclear factor-KB (NF-KB) had been 
associated with caspase-1 (Kannan-Thulasiraman and Shapiro, 2002) and CD 137 (Jang et 
al.，1998), but we were unable to speculate their inter-relationships based on our current 
findings. 
Taken together, the extrinsic and the intrinsic components of apoptotic signaling were 
modulated by ATO. The sequence of action and the role of specific proteins remain to be 
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further deciphered. In addition, the difference in the patterns of apoptotic gene expression 
in CHRF and MEG-01 cells had suggested a possible clue in explaining the biological 
heterogeneity of AMKL from the molecular point of view. 
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(C) Layout of GEArray Q Series Human Apoptosis Gene Array 
Al APAFl D1 CASP13 GI LTA J1 TNFRSF5Ml PUC18 
A2 ASC D2 CASP14 G2 LTB J2 TNFRSF6 Ml PUC18 
A3 ATM D3 CASP2 G3 LTBR J3 TNFRSF7 M3 PVC18 
A4 BAD D4 CASP3 G4 MCLl J4 TNFRSF8 M4 Blank 
A5 BAKl D5 CASP4 G5 MDM2 J5 TNFRSF9 M5 Blank 
A6 BAX D6 CASP5 G6 MYD88 J6 TNFSFIO M6 Blank 
A7 BCLIO D7 CASP6 GI CARD4 J7 TNFSFII Ml GAPD 
A8 BCL2 D8 CASP7 G8 N0L3 J8 TNFSF12 M8 GAPD 
B1 BCL2A1 El CASP8 HI TP73L K1 TNFSF13 N1 PPIA 
B2 BCL2L1 E2 CASP8AP2 H2 CHEK2 K2 TNFSF14 N2 PPIA 
B3 BCL2L11 E3 CASP9 H3 RIPKl K3 TNFSF4 N3 PPIA 
B4 BCL2L2 E4 CFLAR H4 RIPK2 K4 TNFSF5 N4 PPIA 
B5 BIK E5 CHEKl H5 RPA3 K5 TNFSF6 N5 RPLJ3A 
B6 BIRCl E6 CIDEA H6 TANK K6 TNFSF7 N6 RPLJ3A 
B7 BIRC2 E7 CIDEB H7 TNF K7 TNFSF8 N7 ACTB 
B8 BIRC3 E8 CRADD H8 TNFRSFIOA K8 mFSF9 N8 ACTB 
CI BmC4 F1 DAPK2 II TNFRSFIOB LI TP53 
C2 BIRC5 F2 DFFA 12 TNFRSFIOC L2 TMFI 
C3 BmC6 F3 DFFB 13 TNFRSFIOD L3 TRAF2 
"C4 BLK F4 FADD 14 TNFRSF25 L4 TRAF3 
C5 BNIP3 F5 GADD45A 15 TNFRSF14 L5 TRAF4 
C6 BOK F6 HRK 16 TNFRSFIA L6 TRAF5 
CI CASPl F7 msi 17 TNFRSFIB L7 TRAF6 
C8 CASPIO F8 BFAR 18 TNFRSF4 L8 TRIP 
Figure 5.1 cDNA Expression Array Analysis of Apoptosis Regulators in 
ATO-treated CHRF and MEG-01 Cells. 
CHRF and MEG-01 cells were incubated in the absence or presence of 
6 ^M of ATO for 4，8 or 16 hours. RNA was extracted, reversed 
- transcribed, biotin-labeled and hybridized on a GEArray Q-series 
human apoptosis array. Each time point was performed twice 
separately. (A and B) Representative photographs of GEArray 
phosphoimages of CHRF and MEG-01. (C) A table summarizing the 
genes printed on the array is given. The layout was indicated in (A). 
Genes Al to L8 are the 96 apoptosis regulators, while the negative 
controls (Ml - M6) and internal controls (M7 — N8) are located at the 
bottom two rows. Refer to Table 3.2 for details on the gene families. 
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Figures 5.2 一 5.3 Apoptotic Gene Expression Profiles in ATO-treated CHRF and 
MEG-01 Cells at Different Time Points. 
Total RNA was isolated 4, 8 or 16 hours after addition of 6 \xM of 
ATO or vehicle to CHRF or MEG-01 cells. RNA levels were 
analyzed with a GEArray Q series kit. The relative expression of 
apoptotic genes was normalized to the average signal of PPIA 
expression. Plasmid DNA (PUC18) was used as a negative c ontrol 
for background subtraction. Gene expression ratios (treatment versus 
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Figure 5.8 Effects of ATO on Cell Surface DR4 and DR5 Levels in CHRF 
Cells. 
CHRF cells were cultured with 6 |xM of ATO for 0 or 48 hours, and 
incubated with anti-DR4 or DR5 primary, and FITC-conjugated 
secondary antibodies, and analyzed by flow cytometry. (A) The 
staining profiles of DR4 and DR5 of a representative experiment are 
shown. Open histograms indicate the isotype control, while closed 
histograms in gray indicate the expression at 0 hour. Light-scattering 
properties and MFI of the isotype control (figure below Marker Ml) 
are also shown. A region (Rl) was applied to gate out debris. (B) MFI 
of the control and treatment groups are presented as mean and SEM of 
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Figure 5.9 Effects of ATO on Cell Surface DR4 and DR5 Levels in MEG-01 
Cells. 
MEG-01 c cells were cultured with 6 i^M of ATO for 0 or 48 hours, 
and incubated with anti-DR4 or DR5 primary, and FITC-conjugated 
secondary antibodies, and analyzed by flow cytometry. (A) The 
staining profiles of DR4 and DR5 of a representative experiment are 
shown. Open histograms indicate the isotype control, while closed 
histograms in gray indicate the expression at 0 hour. Light-scattering 
properties and MFI of the isotype control (figure below Marker Ml) 
are also shown. A region (Rl) was applied to gate out debris. (B) MFI 
of the control and treatment groups are presented as mean and SEM of 
two independent experiments. 
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(A) MEG-01 CHRF 
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Figure 5.10 Effects of ATO on Protein Levels of Bax and Bcl-2 in CHRF and 
MEG-01 Cells. 
(A) CHRF (right) and MEG-01 (left) cells were treated with ATO at 6 
)iM for 0 - 2 4 hours and the total protein expression was measured by 
Western blot analysis. Actin expression was used as a loading control. 
(B and C) Bax was induced in CHRF and MEG-01 in 4 hours, while 
Bcl-2 appeared to be down-regulated only in CHRF cells. Results are 
presented as the mean and SEM of ratios of the band intensities of Bax 
or Bcl-2 to those of actin, and relative to 0 hour，obtained from two 
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Figure 5.10 Effects of ATO on Protein Levels of Bax and Bcl-2 in CHRF and 
MEG-01 Cells. 
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C H A P T E R 6 
EFFECTS OF ARSENIC TRIOXIDE ON GENE 
EXPRESSION PROFILES OF H U M A N 
MEGAKARYOCYTIC LEUKEMIA C E L L LINES 
BY MICROARRAY ANALYSIS 
SECTION 6.1 Introduction 
In the preceding parts, we have illustrated by various methods that ATO elicited a wide 
range of response in MK cells. In the current chapter, we aimed to capture the primary or 
direct regulatory events at 4 hours, and hence find out the possible mechanism(s) of ATO 
on MK cells. By a 19K microarray, we presented the comprehensive gene expression 
profiles of MK cells in response to ATO. 
SECTION 6.2 Results 
CHRF and MEG-01 cells were exposed to 6 ^M ATO for 4 hours and their gene 
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expression profiles were constructed using the Human 19K Array. These arrays harbor 
19,200 features obtained from the I.M.A.GE. Consortium (Lawrence Livermore National 
Laboratory, Livermore, CA, USA), which comprise 19,008 characterized and unknown 
expressed sequence tags (see http://www.microaiTays.ca/support/glists.html for a 
complete list and array layout). The arrays were analyzed using the TM4 suite. The local 
background for each gene on the array was subtracted, and normalization was performed 
within each array by the LOWES S algorithm, which compensated the systematic bias due 
to the quenching of Cy3 and Cy5 dyes. The effect of normalization was to give a mean 
ratio of 0 at all intensities (Figure 6.1). 
“ > 
The expression data were then put together for clustering using the K-means/K-medians 
method. Apilot analysis suggested that a 11 ignored spots (flagged by the spot 1 ocating 
software) and spots with intensities below detection threshold (i.e. intensity value = 0) 
were excluded (16,420 in CHRF and 17,125 in MEG-01). The removal of these genes 
prior to clustering sped up the process and did not affect the final results. Diagrams of the 
6 clusters obtained from the independent analysis of CHRF and MEG-01 cells are 
portrayed in Figures 6.2，with each gene represented by a line across the six hybridization 
experiments. The eligibility of being allocated into one particular cluster was determined 
by the overall trend of their expression ratios (log2 values). In CHRF, the majority of gene 
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expressions appeared to be not significantly modulated by ATO at 4 hours of exposure, as 
indicated in clusters"2, 3, 4 and 5 (Figure 6.2A). ATO increased the expression of a group 
of genes in cluster 1 and inhibited some genes in cluster 6 (Figure 6 .2Aand 6.2C). 
Similarly, ATO did not seem to have effect on the genes expressions in clusters 1 and 2 of 
MEG-01. Though some genes in clusters 2 and 4 had trends of up-regulation, and a 
tendency to be down-regulated in cluster 6，the majority of them did not have consistent 
changes. Only those genes in cluster 3 appeared to be significantly modulated (Figure 
6.2B). 
In order to address the inherent variations between experiments, and to ensure 
reproducibility of the results, the identification of genes affected by ATO exposure was 
based on a consistent display (affected in four o f six measurements) o f 2.0-fold up or 
down expression changes. As a further measure of significance, the paired r-test between 
the control and the treatment group of each gene was performed. Coincidently, the genes 
that were significantly regulated were those mainly found in clusters 1 and 6 in CHRF, 
and cluster 3 in MEG-01, and that most of the up-regulated genes had statistically 
significant {P < 0.05) increases in expressions over the control group (Tables 6.1 and 
6.2). 
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Using these criteria for analysis, more genes appeared to be regulated in CHRF than in 
MEG-01 cells at 4"hours after exposure to ATO. The number of features differentially 
expressed in CHRF was 23 (actual number of genes was 18 since multiple clones were 
mapped to the same gene), in contrast to 8 (7) in MEG-01. Most of the changes observed 
in gene expression in MK cells were up-regulations. Since none of the genes were 
consistently 2-fold down-regulated, we presented the trend of down-regulation by using a 
less stringent criterion at 1.5-fold decrease (ratio < 0.67) with respect to the control. 
Despite these differences, the identities of genes being up-regulated were remarkably 
similar in the two cell lines. Members of the metallothionein family, heat shock proteins 
and ubiquitin were found to be significantly up-regulated. Other genes such as WTl 
protein and superoxide dismutase were also having trends of increase. No consistent trend 
was observed in the down-regulation side, however (Tables 6.1 and 6.2). 
SECTION 6.3 Discussion 
The gene expression profiles of CHRP and MEG-01 cells in the early response to ATO 
were generated. The microarray analysis revealed that in our experimental conditions, 18 
genes were up-regulated by over 2-fold in four of six hybridizations, and 17 were 
down-regulated (1.5-fold) in CHRF responding to 4-hour 6 ^M ATO exposure. Using the 
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same setting, expression levels of 7 genes were increased and 1 was decreased in 
MEG-01. The majority of the affected genes were common to both cell lines, and were 
mainly involved in metal ion binding (MTIG, MT2A) and protein folding [HSPAIA’ 
HSPCA) activities. Since there were no genes with ratios less than 0.50，the issue of 
possible down-regulation by ATO would not be further discussed. 
In response to adverse physiological or environmental conditions, the cell engages either 
one of the two functionally opposing pathways: stress response, which functions to adapt 
to and counteract the adversity so as to sustain cell survival; and apoptosis, which is a 
• self-destruction program called upon should the damage become unrepairable. Obviously, 
the susceptibility of a cell to damaging stimuli is governed by a coordinated balance 
between these life-or-death processes (Takayama et al” 2003). In previous chapters, we 
have demonstrated that apoptosis was the outcome of MK cells exposed to ATO for at 
least 24 hours. Here in this section, we have shown that stress proteins were immediately 
induced after an acute exposure to ATO (4 hours). 
Rapid induction of stress protein synthesis is a feature of the stress response. The stress 
proteins comprise several families, including metallothioneins, ubiquitin，Hsp90, Hsp70, 
Hsp60, Hsp40, and the small Hsp, classified according to their homology of sequences 
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and molecular sizes. 
Metallothioneins are a group of ubiquitous low molecular weight ( 6 - 7 kDa), cysteine 
rich 30 % of the residues) proteins. The biological functions of metallothioneins are 
still unclear, but they are often associated with the protection against metal toxicity and 
oxidative stress, attributed to its metal-binding property and high cysteine content 
(Klaassen et al.’ 1999). The expression of metallothioneins is both constitutive and 
inducible. Metals, in particular zinc and cadmium, have been shown to be very potent 
inducers of metallothionein I and II isoforms (Park et al., 2001a)，but the effect of 
arsenicals on direct metallothionein induction has been controversial. In in vivo studies, 
trivalent arsenite was shown to induce metallothionein expression in the livers of rat 
(Hochadel and Waalkes, 1997) and mouse (Kreppel et al., 1993; Liu et al., 2001)，but 
Shimizu et al. (1998) failed to reproduce the results in vitro. In human, ATO up-regulated 
metallothionein expression in a kidney cell line (Zheng et al., 2003) and urothelial cells 
(Sens et al, 2003). Such variations in their findings might be explained by the indirect 
involvement of the ROS pathways as induced by ATO (Del Razo et al., 2001; Haq et al., 
2003). Metallothionein induction could alleviate to certain extent the toxicity exerted by 
ATO, as observed in the increased susceptibility of arsenic-induced hepatotoxicity and 
nephrotoxicity in metallothionein-knockout mice (Liu et al, 2000), possibly due to the 
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sequestration of arsenic compounds (Toyama et al.，2002; Jiang et al., 2003). 
Overexpression of metallothioneins is common in tumors, and their basal levels have 
been correlated with increasing tumor grade (Cherian et al., 2003). Recently, doxorubicin-
(Wang et al.’ 2001) and etoposide- (Shimoda et al., 2003) induced apoptosis were 
reported to be suppressed by overexpressing metallothionein levels. The strong induction 
of metallothioneins found in CHRF and MEG-01 might explain the high dose 
requirement of ATO to initiate apoptosis in these cells. 
Regulated protein degradation is one o f t h e strategies in controlling cellular functions. 
• The ubiquitin-proteasome system is one such degradation machinery. Target proteins are 
first covalently linked with poly-ubiquitin chains, then recruited to the 26S proteasome 
where they are rapidly degraded. It has been shown that ATO in the micromolar range 
modulated protein turnover by increasing the attachment of ubiquitin to proteins 
(Kirkpatrick et al.’ 2003). One substrate protein that was increasingly 
ubiquitin-conjugated following ATO exposure was identified to be Cdc25C. The passage 
of the cell into mitosis requires the activation of Cdkl by Cdc25C phosphatase, of which 
the expression level is normally constant throughout the cell cycle. In the presence of 
ATO, Cdc25 was degraded through the ubiquitin-proteasome system, thereby resulting in 
G2/M arrest (Chen et al.’ 2002). In our microarray study, ubiquitin mRNA expression was 
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up-regulated in both CHRF and MEG-01 cells. Concomitant reduction in USP48 (a 
deubiquitinating enzyme) transcript was observed in CHRF. When extrapolated in our 
MK system, these findings suggested a possible link between increased ubiquitination and 
cell cycle arrest. 
Several Hsp members (such as Hsp60, Hsp73) are constitutively expressed and function 
as molecular chaperones by facilitating the folding, assembly, and intracellular 
translocation of newly synthesized proteins (Hartl, 1996; Bukau and Horwich, 1998). 
Others (such as Hsp72) are expressed upon stress-activated regulation of transcriptional 
.response elements. Induction of Hsp synthesis during stress offers cytoprotection by 
refolding non-native proteins to prevent the accumulation of intermediates and formation 
of aggregates, and by inhibiting apoptosis (Beere et ai, 2000; Li et al.’ 2000; Ravagnan et 
al., 2001). It has been known that arsenicals induce a battery of Hsp (Bemstam and 
Nriagu, 2000; Del Razo et al” 2001). Fauconneau et al. (2002) reported ATO-induced 
expression of Hsp could partially block hydrogen peroxide-mediate apoptosis in rat 
astrocytes. In another paper, hydrogen peroxide was suggested to be generated by ATO 
and contributed in cell death (Woo et al., 2002). In the present study, we demonstrated the 
up-regulation of Hsp40 (DNAJBl), Hsp72 (HSPAIA), Hsp73 (HSPAS) and Hsp90 
(HSPCA) expressions in CHRF and MEG-01 cells. This increase in Hsp might probably 
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be correlated with the delay in cell cycle progression as observed in Section 4.2.6 
(Higashikubo et al：, 1993)，and the late onset of apoptotic phenotype found in the MK 
cells, since cell viability was not affected by 4- or 8-hour exposure to ATO (data not 
shown). 
Ferritin is a cellular iron-binding protein, which may be activated by pro-oxidants such as 
hydrogen peroxide (Tsuji et al.，2000). A study in keratinocytes suggested that 
arsenic-induced hydrogen peroxide was responsible for the activation of the transcription 
factor Nrf2 (Pi et al.’ 2003)，which in turn controlled a plethora of oxidative response 
• genes, including ferritin (Pietsch et al., 2003). In a recent proteome analysis, Lau et al. 
(2004) reported an up-regulation of ferritin light polypeptide in rat lung epithelial cells 
treated with arsenic. We showed that the up-regulation of the heavy {FTHl) and light 
{FTL) subunits of ferritin in CHRF cells in response to ATO. The increase in ferritin 
might be related to a concomitant increase in superoxide dismutase expression, since the 
latter enzymatically breaks down superoxide to hydrogen peroxide. Superoxide dismutase 
{SODl) had a trend of up-regulation in CHRF (ratio: 1.90，；？ < 0.05), which essentially 
agreed with findings in mouse liver (Liu et al.’ 2004). Taken together with the 
up-regulation of metallothioneins, it is likely that mechanisms of counteracting ROS were 
activated in MK cells in response to acute ATO exposure. 
127a 
Several genes that were not associated with the stress response pathways were also 
up-regulated in CHRF and MEG-01 cells by ATO. The transcription factor WTl was first 
identified in association with Wilm's tumor (Takahashi et al” 2002), and was found to be 
overexpressed in other tumors, including squamous carcinoma (Oji et al., 2003). 
Nevertheless the molecular actions o f WTl were not clearly characterized. Recently, i t 
was shown that cyclin E expression was suppressed by WTl protein (Loeb et al.，2002). 
In this study, WTl expression levels were increased in CHRF (ratio: 2.44) and in MEG-01 
(ratio: 1.94)，suggesting another possible pathway through which the cell cycle is 
dysregulated. The mRNA expressions of GTP binding protein 4 (GTPBP4) were 
• increased in the two MK cells. However, because of the complexity of the 
GTP-associated pathways, it is difficult to speculate the role played by this gene product 
in the ATO-mediated actions. 
Integrating the mRNA expression results in this chapter, we found that a short duration (4 
hours) of exposure to ATO provoked the protective and repair responses in MK cells, 
despite the heterogeneity nature of MK cells. The effects of these survival mechanisms 
might lead to the observed delay of cell cycle progression and onset of apoptosis. 
However, how all these survival efforts became futile, resulting in apoptosis observed 
hours later is still unclear. 
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This microarray analysis is a part of our ongoing study, which aimed at investigating 
novel candidate genes regulated by ATO in MK cells. In order to elucidate the 
mechanisms of the switch from survival to apoptosis in MK cells, we shall further 
confirm the mRNA and protein expression levels, using real-time quantitative polymerase 
chain reaction and immunoblotting during the course of extended ATO exposure. 
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Figure 6.1 Adjustment of Systematic Bias by LOWESS Normalization. 
RI (ratio-intensity) plots, illustrating the log ratio of each gene (i.e. 
Cy5/Cy3, ordinate) as a function of the product of the individual 
intensity (abscissa) are used to demonstrate the intensity-specific 
effects due to systematic bias. Raw intensity data were 
background-subtracted and the LOWESS normalization algorithm 
was applied. (A) RI plots of pre- (blue, left) and post- (red, right) 
normalized gene expressions are shown. The ratios at all intensities 
were computed to have a mean value of 0. (B) An overlay of the plots 
above. The figures are taken from one hybridization study using 
Cy3-labeled control, and Cy5-labeled ATO treated cDNA. 
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Figure 6.2 Clustering of Gene Expression Profiles of CHRF and MEG-01 
Cells. 
Microarray analysis of the gene expression profile of (A) CHRF and 
(B) MEG-01 cells in response to treatment with ATO at 4 hours was 
performed. Raw intensity data from six hybridizations were 
normalized by MIDAS (TM4 Suite). Of the 19,200 features printed on 
the array, 2,780 (CHRF) or 2,075 (MEG-01) passed various quality 
control and intensity filters, and were input for clustering, using the 
K-means/medians clustering module in MEV software (TM4 Suite) 
with default settings. The clusters are classified according to their 
expression ratios (abscissa) in the six hybridization experiments 
(ordinate). Each line represents a gene. A list of differentially 
expressed genes is summarized in Tables 6.1 and 6.2. (C) 
Representative expression diagrams of clusters 1 and 6 in CHRF. Only 
part of the latter is shown. Each row indicates the expression ratios (in 
log2 values) of one particular gene in 6 separate hybridizations. The 
intensity of red and green colors signifies the magnitude of the up- and 
down-regulation, respectively. 
131a 
Tables 6.1 - 6.2 Genes Regulated by ATO (6 fiM) at 4 Hours in CHRF and 
MEG-01 Cells. 
Gene expression profiles of CHRF and MEG-01 cells exposed to 6 
)iM ATO for 4 hours were obtained from microarray analyses. 
Differentially regulated genes were identified by (a) expression 
levels which were either at least 2-fold above or 1.5-fold below 
control; and (b) consistent expression ratios in at least 4 out of 6 
hybridization experiments. In addition to the expression ratio, 
paired /-test was performed between the two groups using the 
normalized intensity data. An asterisk (*) signifies P < 0.05 
between the control and ATO-treated groups. The functions of the 
translated gene products were obtained from Gene Ontology via 
SOURCE (http://source.stanford.edu) (Stanford Microarray 
Database, Stanford University School of Medicine, Stanford, CA, 
USA). A in the function column indicates that the particular 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































C H A P T E R 7 
GENERAL DISCUSSION AND CONCLUSIONS 
In the present study we have presented that ATO exerted significant and multi-faceted 
influences on the proliferation and functioning of leukemia cells of the MK lineage. In the 
CHRF and MEG-01 cell lines, we observed immediate and likely direct response to ATO 
in the form of protective mechanisms involving metallothionein and hsp gene expressions. 
• Subsequently, these cell lines underwent cell cycle arrest and apoptosis within 24 hours. 
Our attempts to understand the signal pathways of these events, though preliminary, have 
led to the unraveling of some important mechanisms such as the operation of the intrinsic 
！ 
and extrinsic pathways of apoptosis and their possible linkage with cell cycling 
regulations. We have confirmed the finding of various reports on the processes of ATO on 
specific cancer cells. In addition, we provided new information on the signaling of ATO 
such as the activation of the cell surface receptor CD 137 and the transcription factor WTl. 
The differential response of CHRF and MEG-01 cells to ATO insults might be attributed 
to the origin of these lines and reflected the heterogeneous nature of AMKL. As data of 
ATO on MK cells are scant, our results have contributed to the possible incorporation of 
135a 
ATO in the treatment strategy of this leukemia. A summary of the specific findings on the 
effects of ATO on CHRF and MEG-01 is listed in Figure 7.1. 
Several questions have arisen from the current study, which would have to be addressed 
by further investigations. 
(1) Regulatory genes identified from the microarrays at the mRNA level would be 
confirmed by real-time quantitative PCR and their protein expressions investigated 
by immunoblotting/flow cytometry. Significance of the modulation of the extrinsic 
‘ (e.g. c aspase-8 and Fas) and intrinsic (e.g. B ax, B cl-2 andMcl-1) components o f 
apoptosis would be testified by the use of specific inhibitors or small interfering 
RNA. 
(2) Stress response seemed to be the direct effect of ATO in MK cells. How this 
pro-survival response gave way to death signals is unknown at the moment. Time 
course experiments would be required to follow the fate of the stress proteins. 
(3) Some genes, such as CD 137 and WTl have not been associated with the use of ATO, 
nor with MK cells. However, it has been implied that CD 137 was up-regulated in the 
136a 
presence of DNA damaging agents (Kim et aL’ 2002)，and in other reports CD 137 
induced NF-KB (Jang et aL, 1998) or apoptosis (Michel et al., 1999). We thus 
speculate that CD 137 might be involved in either pro-survival or pro-apoptotic 
pathways, as suggested by the dual nature of NF-KB. Further studies along this 
concept could be conducted by Western blot analysis and inhibitors of the NF-KB 
machinery. 
(4) Refractory to chemotherapeutic drugs has become a severe problem and 
well-designed c ombination therapy might avoid the building up of resistance, and 
‘ might reduce the harmful side-effects of individual drugs (Shen et a l , 2004; 
Hochhaus and La Rosee，2004). Our group has previously demonstrated that 
thrombospondin-1 could induce apoptosis in cells bearing CD36, including CHRF 
and MEG-01 cells (Li et al.，2003a). New designer drugs such as tyrosine kinase 
(Abl) inhibitors (e.g. Imatinib) have high efficacies in CML leukemia. In the 
-development of novel treatment protocols for AMKL, the possible synergistic 
activities of ATO in conjunction with these potentially effective agents could be 
studied. 
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A T O 
CHRF and MEG-01 
I r 1 -
Cell Cycle Apoptosis Others 
— 
Extrinsic Intrinsic pathway 
pathway 
(1)Go/Gi,S (mRNA) (1) Av|/m collapse (mRNA) 
phase cells (1) caspase-2 个 （1) caspase-1 个 
reduction 
(2) G2/M arrest (2) caspase-8 个 (mRNA) (2) caspase-5 个 
(3) apoptosis in (3) Fas 个 （2) caspase-2 个 （3) CD 137 个 
all phases (4) DR4 >1 (3) Mcl-l (4) metallothio-
(5) DcR2 个 neins个 
(mRNA) {protein) (5) ubiquitin 个 
(4) WTl 个 (protein) (4) Bax 个 （6) Hsp 个 
(6) Fas 个 （5) Bcl-2 i (7) ferritin 个 
(7) DR4 i (8) superoxide 
(8) DR5 个 dismutase 个 
(protein) 
(9) CD137 个 
Figure 7.1 A Summary of Effects of ATO on CHRF and MEG-01 Cells on 
Cell Cycle Regulation and Apoptosis, as well as the Effects on 
Various Genes Involved in Other Processes. 
个 signifies an increase in expression, i indicates a decrease. 
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